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Chair: Brian T. Denton
Recent advances in the development of new technologies for the early detection and
treatment of cancer have the potential to improve patient survival and lower the cost
of treatment by catching cancer at an early stage. However, there is little research
investigating the health and economic implications of these new technologies. For
example, magnetic resonance imaging (MRI) and new biomarker tests have been
proposed as potential minimally invasive ways to achieve early detection of prostate
cancer. These new technologies vary in their sensitivity and specificity leading to both
false-positive and false-negative results that can have serious health implications for
patients. Moreover, due to the high cost and imperfect nature of these new tests,
whether and when to use these tests is unclear.
We present stochastic models for prostate cancer disease onset and progression
that incorporates partial observability of a patient’s prostate cancer health status.
We used statistical learning algorithms and clinical datasets combined with expert
clinical knowledge of urologists at the University of Michigan to estimate and validate
the models. The models can simulate progression through prostate cancer states to
xiv
mortality from prostate cancer or other causes for a population of patients. New
technologies, such as MRI and biomarker tests, are incorporated into the model using
a probabilistic representation of test outcomes to represent the information these
tests provide about the true health status of the patient. Since these technologies can
be used in varying ways, the choice of tests and optimal times to initiate tests are
treated as decision variables in the model. We calibrated and validated our models
using several data sources and subsequently used our models to design optimal testing
strategies that trade-off the harms and benefits of using these new technologies.
Our results show that these new technologies can lead to significantly improved
health outcomes and they are cost-effective relative to established norms for societal
willingness-to-pay. We have also used these models to provide important insights
about the optimal timing of prostate biopsies for men with low-risk prostate cancer
undergoing active surveillance. By using new technologies to better select men for
biopsy and by improving active surveillance strategies, physicians can reduce the
harms of prostate cancer screening (e.g., unnecessary biopsies and overtreatment of
low-risk disease) while continuing to reduce prostate cancer deaths through screening
and early detection. The methodological approaches we present in this thesis could





Cancer screening has the potential to improve patient survival and lower the cost
of treatment by detecting cancer at an early stage when health outcomes are most
favorable for patients. However, there are several challenges associated with screening
for cancer. For example, the tests used for cancer screening are imperfect and there
are harms associated with the screening process. Additionally, multiple grades of
cancer indicate that, while cancer screening could save the life of a patient with high-
grade cancer, it is unlikely to benefit patients with low-grade cancers. Moreover,
there is uncertainty about progression of cancers over time and uncertainty about the
benefits and side effects of treatment. Finally, the benefits of cancer screening depend
on all-cause mortality, since patients with a lower expected lifespan are unlikely to
receive the benefits of screening. Due to these issues, decisions about cancer screening
are challenging.
Prostate cancer is the ideal context to explore these challenging problems because
of (1) its societal importance (one in six men are diagnosed in the United States); (2)
the prostate-specific antigen (PSA) test is an existing biomarker that is in common
use; and (3) many new prostate cancer screening biomarkers have recently been de-
veloped. Additionally, prostate cancer can have slow progression, and patients with
different grades of prostate cancer have significantly different treatment options and
1
survival outcomes.
Prostate cancer is the most common cancer among men in the United States. The
risk of developing prostate cancer varies among patients depending on many factors.
For example, patients who are African-American or have a family history of prostate
cancer are considered to be at a higher risk for the disease. Since prostate cancer
is asymptomatic at early stages, some physicians screen their patients for prostate
cancer using digital rectal examinations (DRE) and the PSA test. If the results of
these tests are “suspicious”, a biopsy is performed.
Two recent clinical trials to evaluate the effectiveness of PSA screening for pre-
venting prostate cancer death have resulted in contradictory findings. The European
Randomized Study of Screening for Prostate Cancer (ERSPC), Schröder et al. (2009,
2012, 2014), randomized 162,387 men to either a screening group or a control group at
seven centers in European countries. The relative risk after 11 years of follow-up was
a statistically significant 0.79 between the screening and control arms, interpreted as a
20% risk reduction in prostate cancer mortality due to early diagnosis and treatment.
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, Andriole et al.
(2009), randomized 76,693 men to either a screening group or a control group at 10
centers in the United States. The relative risk of prostate cancer mortality after 13
years of follow-up was a non-statistically significant 1.09 between the screening and
control arms, showing no benefit from early diagnosis and treatment (Andriole et al.
(2012)). These conflicting findings suggest that randomized control trials are not the
ideal way to evaluate screening policies. Due to these conflicting findings, there is
disagreement about if and when men should be screened. For example, the American
Urological Association (AUA) recommends PSA screening for men from ages 55 to 69
with two year intervals (Carter et al. (2013)), while the U.S. Preventive Services Task
Force recommends against PSA screening due to the over-treatment and unnecessary
biopsies that have been attributed to wide-spread PSA screening (Moyer (2012)).
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Thus, in this thesis we study optimal approaches to conduct screening in a manner
that reduces unnecessary biopsies and the overtreatment of low-grade prostate cancer.
Recent advances in the development of new technologies for the early detection of
prostate cancer have the potential to supplement the PSA test and improve patient
survival by catching cancer at an early stage when health outcomes are most favorable
for patients. However, there is little research investigating the long-term health and
economic implications of these new technologies. For example, magnetic resonance
imaging (MRI) and new biomarker tests have been proposed as potential minimally
invasive ways to achieve early detection of prostate cancer, but whether and when to
use them is unclear due to the high cost and imperfect nature of these tests.
Several new diagnostic prostate cancer biomarkers have been recently discovered
(Makarov et al. (2009); Tosoian et al. (2016)). Some of these biomarkers are PSA
derivatives, such as free PSA and [-2]proPSA. Some of the biomarkers are based on
combinations of serum markers, such as the prostate health index (phi), which uses a
combination of total PSA, free PSA, and [-2]proPSA to generate a score (Bryant and
Lilja (2014); Catalona et al. (2011)), and the 4Kscore, which uses a panel of total
PSA, free PSA, intact PSA, and human kallikrein-2 (hK2) to estimate a patient’s
risk of high-grade cancer (Gleason score ≥ 7) on biopsy. Other molecular biomarkers
include prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG (T2:ERG), which are
detectable in post-DRE urine (Bussemakers et al. (1999); Salagierski and Schalken
(2012); Truong et al. (2013); Tomlins et al. (2005); Brenner et al. (2013); Pettersson
et al. (2012); Young et al. (2012)). The Mi-Prostate Score (MiPS) early detection
test combines a patient’s serum PSA, urine PCA3 score, and urine T2:ERG score
into a single multivariate regression model to estimate individualized risk estimates
for all prostate cancer and high-grade prostate cancer (Tomlins et al. (2016)). These
tests vary in the outcome they predict (all-cancer versus high-grade cancer) and in
their sensitivities and specificities. No previous study has compared these biomarkers
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to determine which characteristics achieve optimal long-term health outcomes in the
context of early detection of prostate cancer.
MRI has recently been proposed as another potential minimally invasive way to
achieve early detection of prostate cancer. MRI has higher sensitivity and specificity
to high-grade disease than molecular biomarkers, so MRI could potentially reduce
overtreatment by preferentially detecting intermediate- and high-grade cancers (Sid-
diqui et al. (2015); Meng et al. (2016); Oberlin et al. (2016); Siddiqui et al. (2016)).
However, MRI is more costly than molecular biomarkers and there is limited evidence
for its effectiveness as an intermediate test in patients being screened for prostate can-
cer. Moreover, there are multiple ways to use MRI in a screening setting, and it is
not clear which is best.
Based on biomarker test results, MRI results, or other clinical findings, a patient
may be recommended to have a biopsy. During a biopsy, a hollow core needle is used
to remove between 6 and 24 (usually 12) core samples of tissue from the prostate
to determine if the tissue is malignant. Biopsies have a specificity close to 1 and a
sensitivity of approximately 0.8 according to studies in the literature (Terris (1999)).
Biopsies are painful, may cause bleeding and infection, and can be a source of anxiety
for patients (Wade et al. (2013)). If cancer cells are found upon evaluation of the
biopsy by a pathologist, the cells are given a Gleason score. The two most common
tissue patterns of the prostate tissue (obtained during the biopsy) receive a grade
between 1 and 5. This grade rates how different the cancer cells are from normal
cells. These two grades are added together to obtain a Gleason score between 2 and
10. A higher Gleason score indicates that the tumor is more likely to grow and spread
quickly.
Once a patient has been diagnosed with prostate cancer, a physician needs to
determine the stage of the disease. During clinical staging, it is important to detect
metastatic disease (i.e. when the cancer has spread to other parts of the body),
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because this determines treatment options. Thus, a computed tomography (CT)
scan or bone scan may be performed to screen patients with a high risk of metastatic
disease. CT scans and bone scans are used to detect whether the cancer has spread
to the lymph nodes and the bones, respectively.
Following diagnosis there are many factors that influence treatment decisions,
including the stage and grade of the cancer, the age and life expectancy of the patient,
possible side effects, and whether the patient has other health conditions. If a patient
is diagnosed with metastatic cancer, they will most likely receive hormone therapy or
chemotherapy. For localized cancer there are several treatment options.
Radical prostatectomy is the surgical removal of the prostate gland and surround-
ing tissue, and is an appropriate treatment option when the cancer is contained within
the prostate. This procedure can be done as an open surgery or laparoscopically,
which affects the recovery time. Radical prostatectomy has the same risks as other
major surgeries including infection, blood loss, and heart problems. Some possible
long-term side effects include impotence, urinary incontinence, and damage to the
urethra or rectum; however, it is usually effective in curing early-stage prostate can-
cer.
For men with low-grade cancer, there are currently two types of observational
treatment strategies, known as expectant management, that can serve as alternatives
to aggressive immediate treatments. Watchful waiting is an expectant management
option that delays curative treatment until symptoms arise. Active surveillance is an
expectant management option for patients with low-risk prostate cancer that delays
and possibly avoids curative treatment until there is evidence that the disease has
progressed; however, the patient must undergo repeated biopsies and there is still
the potential for the cancer to progress due to the imperfect nature of surveillance
biopsies. Expectant management has the benefit that it allows men to delay and
possibly avoid the side effects of curative treatment; however, the optimal timing of
5
biopsies during active surveillance is unknown.
The two main harms of prostate cancer screening are unnecessary biopsies caused
by false-positive PSA results and the overtreatment of low-risk prostate cancer with
harsh curative treatments. The goal of this thesis is to discover ways to reduce the
harms of prostate cancer screening by providing insights on how new technologies can
be used with the established PSA test to better select men for prostate biopsy, as well
as improve the understanding of risks associated with active surveillance strategies to
encourage patients and physicians to reduce overtreatment in favor of active surveil-
lance. By reducing the harms associated with screening, physicians can safely screen
men for prostate cancer and reduce prostate cancer deaths. To achieve these goals we
describe stochastic models we developed and validated that cover the complete life
cycle of prostate cancer from early ages when the probability of prostate cancer is low,
through potential onset and progression of cancer, and subsequent treatment. These
models are used to answer key questions about prostate cancer, such as whether,
when, and how to use new technologies or procedures judiciously to improve quality
of life and lifespan for men.
This dissertation is structured as follows. In Chapter II we present a literature
review on simulation and optimization of cancer modeling. In Chapter III, we present
a prostate cancer simulation model that we used to evaluate a wide range of new
biomarkers for the early detection of prostate cancer in patients with elevated PSA. In
Chapter IV, we present cost-effectiveness analysis of using MRI for the early detection
of prostate cancer in men with elevated PSA. In Chapter V, we develop a partially
observable Markov decision process (POMDP) to determine optimal prostate biopsy
decisions using new biomarkers. In Chapter VI, we use longitudinal data from the
Johns Hopkins Active Surveillance study to create a hidden Markov model that we
used to develop optimal biopsy follow-up schedules for patients with low-risk prostate
cancer. Finally, in Chapter VII we discuss the main findings from this dissertation
6




The scope of this literature review includes simulation and optimization models for
cancer screening. It is a narrative review that describes related literature. We provide
a more specific discussion of the most relevant literature in each of the following
chapters.
2.1 Simulation Models
Many models have studied the lead time and overdetection of prostate cancer,
where the lead time of prostate cancer refers to the advanced time of diagnosis re-
sulting from the use of biomarker tests, and overdetection of prostate cancer refers to
patients who are diagnosed with prostate cancer that would not have been diagnosed
in the absence of screening. Etzioni et al. (2002) developed a computer simulation
model of PSA testing and prostate cancer to provide estimates of overdiagnosis due
to PSA screening. They found that the majority of screen-detected cancers between
1988 and 1998 would have presented clinically in the patient’s lifetime, and therefore
were not overdiagnosed. Draisma et al. (2003) developed simulation models using
the outcomes of the Rotterdam section of the ERSPC to predict mean lead times
and overdetection rates of different screening policies. Based on their results, they
concluded that a screening interval of more than one year would be optimal. Tsodikov
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et al. (2006) used a statistical model to estimate prostate cancer screening charac-
teristics, such as lead time and overdiagnosis, to try to find a connection between
the onset of PSA screening and population responses observed in Surveillance, Epi-
demiology, and End Results (SEER) registry data. Draisma et al. (2009) presented
three independent prostate cancer models that were developed using SEER registry
data to estimate the lead time of the disease, as well as the overdetection rate. They
found that their estimated lead times were similar, but differed based on the defi-
nition used, concluding that the definition of lead time in models should always be
clearly defined. Savage et al. (2010) developed an empirical lead time distribution
between an elevated PSA (≥ 3 ng/mL) and subsequent prostate cancer diagnosis,
and found that there was wide variation in lead times, with longer lead times having
a lower risk of high-grade disease. Gulati et al. (2014) developed a nomogram that
provides patients with individualized estimates of the risk that their screen-detected
prostate cancer is overdiagnosed, based on the patient and tumor information known
at diagnosis. Important factors in determining the chance of overdiagnosis are age,
Gleason score, and PSA at diagnosis.
There have also been many models that have estimated the effect of widespread
PSA-screening on prostate cancer statistics. Etzioni et al. (2008a) developed a fixed-
cohort simulation model of prostate cancer screening to determine the impact of
PSA screening on the incidence of advanced stage prostate cancer in the United
States. They determined that PSA screening accounted for 80% of the observed
decline in distant stage incidence, but concluded that other factors have most likely
also contributed to the decline, such as improved treatment modalities and increased
awareness. Etzioni et al. (2008b) presented two mathematical models that use SEER
registry data to project mortality increases in the absence of screening and decreases
in the presence of PSA screening. The models found that 45% to 70% of the observed
decline in prostate cancer mortality in the United States could be attributed to PSA
9
screening.
There have also been studies that compared the effectiveness of alternative PSA
screening policies (e.g. annual screening or biennial screening, varying starting age for
screening). Ross et al. (2000) compared prostate cancer mortality, PSA testing rates,
and biopsy rates for several different PSA screening strategies using a Markov Chain-
based Monte Carlo simulation. They found that a policy that begins earlier than age
50 and screens biennially instead of annually would perform better than screening
annually beginning at age 50. Gulati et al. (2013) developed a microsimulation model
of prostate cancer to evaluate the effectiveness of PSA-based prostate cancer screening
strategies. They evaluated strategies recommended by guidelines and 32 combinations
of two ages to start screening, two ages to end screening, two screening intervals, and
four PSA thresholds for biopsy. They concluded that PSA screening strategies that
have higher thresholds for biopsy referral for older men and that screen men with
low PSA levels less frequently performed better than standard screening in terms of
minimizing both the harms of screening and prostate cancer deaths.
Gulati et al. (2011) developed a simulation model to project long-term estimates of
the number needed to screen and the number needed to treat to prevent one prostate
cancer death with PSA screening from ERSPC, and found that their long-term esti-
mates are much more favorable than the previous short-term estimates published by
Schröder et al. (2009). Heijnsdijk et al. (2012) presented a Microsimulation Screening
Analysis (MISCAN) model based on ERSPC follow-up data to predict various long-
term prostate cancer screening outcomes. Heijnsdijk et al. (2015) used the MISCAN
model to evaluate the cost-effectiveness of prostate cancer screening, and concluded
that prostate cancer screening can be cost-effective when the patient receives two or
three screenings between ages 55 and 59 years. Roth et al. (2016) also studied the
cost-effectiveness of PSA screening using a microsimulation model; however, their
cohort was based on a US population. Roth et al. (2016) concluded that for PSA
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screening to be cost effective, it needs to be used conservatively with conservative
management approaches for low-risk disease.
Underwood et al. (2012) developed a genetic algorithm simulation optimization
model based on a non-stationary finite horizon Markov chain to develop a PSA screen-
ing policy that maximizes expected quality-adjusted life years (QALYs). The genetic
algorithm uses tournament selection to choose parents, two-point crossover to create
offspring, and elitism and mutation to create the next generation. The policy gener-
ated by the genetic algorithm performed better than previously published policies in
terms of QALYs. The simulation optimization model indicated that patients should
be screened more aggressively for a shorter period of time.
Several studies have developed models to evaluate new technologies for the early
detection of prostate cancer. Heijnsdijk et al. (2016) used MISCAN to evaluate the
effects of the new biomarker, phi, on prostate cancer screening. They concluded that
the use of phi in patients with elevated PSA substantially reduced the number of
negative biopsies and improved the cost-effectiveness of prostate cancer screening.
Birnbaum et al. (2015) used a simulation model to evaluate the effect of the new
biomarker, PCA3, on prostate cancer screening, and found that supplementing PSA
with the PCA3 test significantly reduced adverse screening outcomes. Willis et al.
(2014) performed a clinical decision analysis and de Rooij et al. (2014) performed a
cost-effectiveness analysis of using MRI followed by targeted prostate biopsy for early
detection of prostate cancer. Willis et al. (2014) found that using MRI resulted in
fewer biopsies and more clinically significant cancer diagnoses, while de Rooij et al.
(2014) found that using MRI resulted in similar costs to the current standard of care
while achieving more QALYs.
Active surveillance is a treatment option for low-risk prostate cancer patients
that delays or avoids curative treatment until there is evidence of disease progres-
sion; however, the patient must receive serial prostate biopsies, there is the potential
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for misclassification at diagnosis due to undersampling at biopsy, and the optimal
timing of biopsies during surveillance is unknown. Inoue et al. (2014) used serial
prostate biopsy data from the Johns Hopkins Active Surveillance study to explore
whether Gleason score upgrading during active surveillance was due to misclassifica-
tion or true grade progression. Inoue et al. (2014) developed a statistical model that
estimated true grade progression rates, while accounting for misclassification due to
undersampling at diagnosis biopsy. They applied their model to serial prostate biopsy
results for patients enrolled in active surveillance at Johns Hopkins, and concluded
that tumor grade can progress in low-risk prostate cancer patients. In a related blad-
der cancer study, Zhang et al. (2013) studied the optimal timing of cystoscopies for
patients with low-grade noninvasive bladder cancer. They developed a partially ob-
servable Markov model to estimate QALYs, expected lifelong progression probability,
and lifetime number of cystoscopies for varying surveillance strategies.
There have also been a number of related studies in the context of breast can-
cer. Maillart et al. (2008) considered the problem of how often premenopausal and
post-menopausal women should receive mammography screening for breast cancer.
They formulated a partially observable Markov chain for breast cancer progression
including five states. The model assumes that patients are only diagnosed with breast
cancer during routine screening. Thus, the model provides a conservative, worst-case
scenario analysis, since some patients would develop symptoms and be diagnosed be-
tween screening. Unlike previous models, their model addressed multiple age-based
dynamics of breast cancer screening. Since adherence to the current routine policy
recommendation is low, Maillart et al. (2008) only considered “two-phase” policies,
which consist of only two different screening intervals. The experimental design of
Maillart et al. (2008) resulted in 1223 enumerated possible policies, and sample-path
enumeration was used to generate a frontier of efficient policies by balancing the life-
time mortality risk and the expected number of mammograms throughout a patient’s
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lifetime. The current recommendation of annual mammograms beginning at age 40
is dominated by less than 1% by the frontier efficient policies. Maillart et al. (2008)
provides a range of efficient and less than 1% efficient policies that patients can select
from based on their personal preferences. It was determined that screening should
start relatively early and end relatively late in life regardless of the interval between
mammograms.
Tejada et al. (2015) developed a natural history simulation model of breast cancer
in a simulated population of women in the United States over age 65. Tejada et al.
(2014) used the natural histories of the simulated population to model breast cancer
screening for women over age 65. They combined discrete-event simulation and system
dynamics submodels to compare screening policies based on overall cost-effectiveness,
cost incurred, and the numbers of life-years and QALYs saved. They considered inter-
val screening policies (i.e. one policy for the entire population), risk-based screening
policies, and factor-based screening policies accounting for factors such as age, race
and body mass index. Their final recommendation is annual screening between ages
65 and 80.
Mandelblatt et al. (2016) was a collaboration of six simulation models that eval-
uated breast cancer screening outcomes, accounting for recent advances in mam-
mography and treatment. They found that biennial breast cancer screening with
mammography is efficient for average-risk patients, and that optimal starting ages
and screening intervals depend on patient characteristics and preferences. Ayer et al.
(2015) found that since adherence to mammography screening policies is imperfect
and heterogeneous, an aggressive screening strategy recommending annual screening
to the general population should be recommended.
Similar studies have been published related to lung cancer screening. For example,
de Koning et al. (2014) conducted a comparative modeling study using five indepen-
dent models, and suggested annual lung cancer screening with CT for patients age
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55 to 80 with ≥ 30 pack-years of smoking. This screening policy resulted in 50% of
cases diagnosed at an early stage and a 14% reduction in lung cancer mortality.
2.2 Optimization Models
There have been a number of previous studies that have used optimization models
to investigate screening and treatment decisions for cancer in the context of imperfect
screening tests.
Zhang et al. (2012a) developed a nonstationary POMDP for prostate biopsy refer-
ral decisions that maximizes expected QALYs, and found that the decision of when
to stop screening is highly dependent on the patient and the disutility of life after
treatment. It is proven that there exists a control-limit type policy, and the computa-
tional experiments performed indicate that there is a nondecreasing belief threshold
in age. Sufficient conditions for discontinuing PSA screening for older patients are
presented. Zhang et al. (2012b) expanded on this work by including PSA screening
decisions about whether and when to screen over the course of a patient’s lifetime.
Zhang (2011) presents a POMDP for prostate cancer treatment decisions, incorporat-
ing active surveillance. At each decision epoch, the patient can wait, receive a PSA
test or biopsy, or receive definitive treatment. The underlying partially observable
Markov chain formed the initial basis of the model that we developed and validated,
which we describe in Chapter III.
Lavieri et al. (2012) investigated a model to optimize the timing of when to begin
radiation therapy in prostate cancer patients based on the patient’s PSA level. Their
model balances the risk of beginning radiation therapy too soon before hormone
therapy has achieved its maximum effect with the risk of beginning radiation therapy
too late when tumor cells become resistant to treatment.
Simmons Ivy et al. (2009) developed a simulation model that combines statisti-
cal control and a POMDP to quantify the impact of variability and noise on patient
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outcomes in breast cancer decision making. They found that variability among radiol-
ogists in interpreting mammography results has the largest impact on a patient’s out-
comes. Thus, reducing this variability should be a primary goal to improve women’s
healthcare.
Chhatwal et al. (2010) developed a finite-horizon discrete-time Markov decision
process for breast biopsy referral decisions. The model takes into account a patient’s
mammographic features and demographic factors. The optimal policy shows that
there is a control-limit type policy based on the patient’s breast cancer risk and
nondecreasing control-limits with age. Using clinical data, their model outperforms
radiologists in the biopsy decision-making problem, which may have the ability to
reduce the variability noted in Simmons Ivy et al. (2009).
Ayer et al. (2012) was the first paper to consider personalized mammography-
screening policies, based on both static and dynamic risk factors. They develop a
discrete-time, finite-horizon POMDP model to determine the optimal policy for an
individual patient in terms of maximizing the total expected QALYs. The POMDP
consists of six states, including multiple cancer states. Every six months, based on
the woman’s current risk of breast cancer a decision is made about whether the pa-
tient should receive a mammogram or should wait six months. In this model, if a
mammogram comes back positive, the patient receives a biopsy, which is assumed to
be perfect. Ayer et al. (2012) also incorporates the possibility of self-detection into
the problem, and shows that self-detection increases the total expected QALYs, while
reducing the number of mammograms. This POMDP is solved optimally using Mon-
ahan’s algorithm; however their results are sensitive to the disutility values associated
with a mammogram.
Models have also been used to optimize cancer screening and treatment decisions
for colorectal cancer. For example, Erenay et al. (2014) developed a POMDP to
optimize colonoscopy screening policies to maximize expected QALYs. They report
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that optimal screening policies recommend women with a history of colorectal cancer
should be screened via colonoscopy more frequently than men, while women without
a history of colorectal cancer should be screened via colonoscopy less frequently than
men.
2.3 Contributions to the Literature
Zhang et al. (2012a) and Underwood et al. (2012) developed models to study opti-
mal prostate cancer screening policies that maximize expected QALYs; however, both
of these models only have one preclinical cancer state. Approximately half of screen-
detected cases are considered low-risk with slow growing tumors, and these patients
have different treatment options than patients with high-risk tumors. Thus, our work
extends that of Zhang et al. (2012a) and Underwood et al. (2012) by accounting for
different grades of prostate cancer, and can therefore differentiate between different
treatment options for patients. Our simulation models in Chapters III and IV also
contribute to the literature by evaluating new prostate cancer diagnostic biomarkers
and MRI, including multi-stage approaches for using these new technologies. Our
work provides a way to directly compare the long-term health impacts of these new
technologies. Additionally, we have included behavioral aspects of treatment choice
into our simulation models by using a predictive model for active surveillance selec-
tion. In Chapter V, we developed a POMDP, which we solved using a new data-driven
sampling approach to develop a set of relevant grid points in the belief space based
on our special problem structure. Finally, in Chapter VI we present what is, to the
best of our knowledge, the first hidden Markov model based on longitudinal active
surveillance data. We fit our model using data from 1499 patients enrolled in ac-
tive surveillance at Johns Hopkins over 20 years. Using this hidden Markov model,
we quantified the trade-off among a large number of biopsy strategies and provide
insights about how to improve upon strategies proposed in the literature.
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CHAPTER III
A Simulation Model of Prostate Cancer Screening
Decisions Using Newly Discovered Biomarkers
3.1 Introduction
Although prostate cancer is the most common solid tumor in American men,
there is controversy surrounding prostate cancer screening. The AUA recommends
shared decision-making for men from ages 55 to 69 considering PSA-based screening,
and specifies screening intervals of two years preserve the majority of the benefits of
screening and reduce overdiagnosis and false positives (Carter et al. (2013)). How-
ever, the U.S. Preventive Services Task Force recommends against prostate cancer
screening with the PSA test due to the potential harms from unnecessary biopsies
and overtreatment of low-risk disease (Moyer (2012)). In recent years many new
biomarkers have been discovered for early detection of prostate cancer that may be
able to supplement the PSA test to reduce unnecessary biopsies. Patients and their
healthcare providers now have access to these new biomarkers which could potentially
be combined into multi-stage biomarker screening strategies that improve the preci-
sion with which screening can be performed. These discoveries have the potential to
improve patient survival and lower the burden of screening by better discriminating
between patients with and without cancer. However, these tests vary in their predic-
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tive characteristics, and the ideal way to use them to achieve optimal long-term health
benefits is unclear. In this chapter we study the question of how to design two-stage
biomarker screening strategies in the context of prostate cancer. A two-stage strategy
uses one biomarker (e.g. PSA) to stratify patients into two groups that either receive
biopsy or no biopsy and a third group that receives a second stage biomarker test.
Such strategies have to potential to better select men for biopsy.
Several new diagnostic prostate cancer biomarkers have recently come to market
(Makarov et al. (2009); Tosoian et al. (2016)). Some of these biomarkers are PSA
derivatives, such as free PSA and [-2]proPSA. Some of the biomarkers are based on
combinations of serum markers, such as phi, which uses a combination of total PSA,
free PSA, and [-2]proPSA to generate a score (Bryant and Lilja (2014); Catalona et al.
(2011)), and the 4Kscore, which uses a panel of total PSA, free PSA, intact PSA, and
hK2 to estimate a patient’s risk of high-grade cancer (Gleason score ≥ 7) on biopsy.
Other molecular biomarkers include PCA3 and T2:ERG, which are detectable in post-
DRE urine (Bussemakers et al. (1999); Salagierski and Schalken (2012); Truong et al.
(2013); Tomlins et al. (2005); Brenner et al. (2013); Pettersson et al. (2012); Young
et al. (2012)). The MiPS early detection test combines a patient’s serum PSA, urine
PCA3 score, and urine T2:ERG score into a single multivariate regression model to
estimate individualized risk estimates for all prostate cancer and high-grade prostate
cancer (Tomlins et al. (2016)). These tests vary in the outcome they predict (all-
cancer versus high-grade cancer) and in their sensitivities and specificities. No study
has yet attempted to compare these biomarkers to determine which characteristics
achieve optimal long-term health outcomes in the context of early detection of prostate
cancer.
In order to better understand the optimal design of screening strategies in a multi-
biomarker setting, we estimated long-term health outcomes using a partially observ-
able Markov model. We validated the model by comparing model-based estimates of
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health outcomes with independent estimates reported in the literature. Based on the
AUA screening policy, we compared each of the biomarkers in the context of patients
who were screened from ages 55 to 69 with a screening interval of two years. Dur-
ing each screening period, we employed an innovative two-stage biomarker screening
strategy. If the patient’s serum PSA was over a specified threshold (2 or 4 ng/mL), a
second biomarker test was administered. We estimated the number of prostate cancer
deaths and screening biopsies per 1000 men, as well as the gain in QALYs compared
to no screening in order to identify the ideal biomarker characteristics. We drew con-
clusions about optimal screening strategy design characteristics that may generalize
to other disease contexts in which multiple biomarkers can be used to achieve early
detection.
3.2 Model
To evaluate screening strategies that use biomarkers of varying sensitivity and
specificity, we developed a partially observable Markov model in which pretreatment
states are not directly observable. Biomarker tests give (imperfect) information about
the true state of the patient. The partially observable pretreatment states in the
model include no prostate cancer, undetected organ-confined prostate cancers based
on Gleason score (GS < 7, GS = 7, GS > 7), and extraprostatic or lymph node-
positive cancer (EPLN). The EPLN state aggregates these two conditions into one
state because they are similarly associated with decreased survival. The states were
selected because they distinguish patients on the basis of likely treatment options,
outcomes, and survival.
3.2.1 Model Parameters
Figure 3.1 displays the health states and possible state transitions for the model.
Each year that the screening strategy calls for testing the following sequence of events
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Figure 3.1: State transition diagram. Health states and progression paths in the
Markov model are shown, where transitions between states are repre-
sented by arrows. Patients who are detected with prostate cancer (PCa)
are treated immediately with radical prostatectomy (RP) or active surveil-
lance (AS). GS = Gleason score; EPLN = extraprostatic or lymph node-
positive cancer.
in the model occur: the patient receives one or more biomarker tests according to the
specified strategy; the biomarker test results determine whether a biopsy is performed;
and the patient transitions to their next health state. As our model focuses on
screening of the general population, the screening strategy terminates after an initial
biopsy and the patient continues to make state transitions in the absence of screening
until reaching one of the absorbing states, all-other-cause mortality or prostate cancer
mortality. The parameters used to calculate the transition probabilities are described






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Annual transition rate from No PCa to GS < 7 (wt); We assume that when
patients are in No PCa, they can only transition to organ confined GS < 7 or death,
which is consistent with the assumption made in Draisma et al. (2003). In Figure
2 of Haas et al. (2007), the predicted proportion of patients with prostate cancer is
reported by age based on needle biopsies on autopsy prostates. Let wt be the annual
transition probability from No PCa to GS < 7 during the period from t to t+ 1. Let
at and at+1 be the predicted proportion of patients with prostate cancer at age t and
age t+1, respectively. Let Nt and Nt+1 denote the size of the male population at age
t and t + 1, respectively. Then, wt is the cumulative incidence over the age range t











number of prostate cancer patients who developed prostate cancer at age t and are
still alive at age t+ 1, and (1−at)wtNt Nt+1Nt is the number prostate cancer patients at
age t+ 1 who did not have prostate cancer at age t. Note that in a closed population,
Nt > Nt+1. Thus, the ratio
Nt+1
Nt
is the proportion of age t patients who live to age




We used this equation to calculate the annual transition rates based on the estimates
of at reported in Haas et al. (2007).
Annual other-cause mortality rate (dt); The annual other-cause mortality
rate was obtained from the CDC Life Tables (Arias (2010)).
Annual metastasis rate for patients with undiagnosed prostate cancer
(et); Since the metastasis rate for patients with undiagnosed prostate cancer is un-
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observed, we calibrated the values of et with respect to long-term outcomes reported
in the literature. Specifically, we varied the metastasis rate in 10-year periods, and
calibrated the values so the resulting age-dependent risk of prostate cancer death un-
der routine screening matched the values reported in the literature (Howlader et al.
(2012)):





For calibration, 30,000,000 samples were taken and confidence intervals were







Annual prostate cancer-specific mortality rate given metastasized prostate
cancer (zt); Let St be defined as the five-year prostate cancer-specific survival rate
for metastasized prostate cancer at age t. Then we can calculate annual prostate
cancer-specific mortality rate given metastasized prostate cancer, zt, as:
zt = 1− S1/5t
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Table 22.5 of Ries et al. (2007) reports the 5-year prostate cancer-specific mortality
rate for metastasized prostate cancer to be 0.319, 0.366, and 0.368 for age groups
20–64, 65–74, and 75+, respectively. Thus,
zt =

0.204, if t ≤ 64
0.182, if 65 ≤ t ≤ 74
0.181, if t ≥ 75
Sensitivity of prostate biopsy procedure (f); Haas et al. (2007) reported
the sensitivity of biopsy from the mid peripheral zone and the lateral peripheral zone
combined for clinically significant cancer to be 80%.
Annual transition rate calculations from Draisma et al. (2003); The
model in Draisma et al. (2003) has three localized stages (Loc G1, Loc G2, Loc
G3). Loc G1 is equivalent to organ confined GS < 7 PCa in our model, Loc G2 is
equivalent to organ confined GS = 7 PCa in our model, and Loc G3 is equivalent to
organ confined GS > 7 PCa in our model. The model in Draisma et al. (2003) has
three regional stages (Reg G1, Reg G2, Reg G3), and our model has one regional state
(EPLN). Draisma et al. (2003) reported the average dwelling time (µ) for each state.
We used these reported dwelling times to calculate stationary transition probabilities
between states. For a discrete-time Markov chain, we let Ti be the time spent in
state i before transitioning to another state. Ti is a random variable of geometric
distribution, which has a mean of 1
p
where p is the annual transition rate of leaving




• Annual transition rate from GS < 7 to GS = 7 (o1o2); Draisma et al.
(2003) reported the average dwelling time in Loc G1 to be 6.95, and reported
that 0.7 proportion of patients departing Loc G1 transition to Loc G2. Thus the
transition rate of leaving the state of GS < 7 is 1
6.95
= 0.144, and the transition
rate from GS < 7 to GS = 7 is 0.144× 0.70 = 0.101.
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• Annual transition rate from GS = 7 to GS > 7 (o2o3); Draisma et al.
(2003) reported the average dwelling time in Loc G2 to be 4.81, and reported
that 0.42 proportion of patients departing Loc G2 transition to Loc G3. Thus
the transition rate of leaving the state of GS = 7 is 1
4.81
= 0.208, and the
transition rate from GS = 7 to GS > 7 is 0.208× 0.42 = 0.087.
• Annual transition rate from GS < 7 to EPLN (o1e); Draisma et al.
(2003) reported the average dwelling time in Loc G1 to be 6.95, and reported
that 0.2 proportion of patients departing Loc G1 transition to regional disease.
Thus the transition rate of leaving the state of GS < 7 is 1
6.95
= 0.144, and the
transition rate from GS < 7 to EPLN is 0.144× 0.20 = 0.029.
• Annual transition rate from GS=7 to EPLN (o2e); Draisma et al. (2003)
reported the average dwelling time in Loc G2 to be 4.81, and reported that 0.39
proportion of patients departing Loc G2 transition to regional disease. Thus the
transition rate of leaving the state of GS = 7 is 1
4.81
= 0.208, and the transition
rate from GS = 7 to EPLN is 0.208× 0.39 = 0.081.
• Annual transition rate from GS > 7 to EPLN (o3e); Draisma et al. (2003)
reported the average dwelling time in Loc G3 to be 5.25, and reported that 0.51
proportion of patients departing Loc G3 transition to regional disease. Thus the
transition rate of leaving the state of GS > 7 is 1
5.25
= 0.190, and the transition
rate from GS > 7 to EPLN is 0.190× 0.51 = 0.097.
Metastasis of treated prostate cancer (pnc, g); Metastasis following radical
prostatectomy depends on the stage of the disease at treatment. There are two
post-treatment states patients can transition to following treatment: no recurrence
following treatment (NRFT) and possible recurrence following treatment (PRFT).
If a patient has organ-confined disease at surgery, they transition directly to NRFT
following radical prostatectomy. Patients who transition to NRFT have been cured
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and will not develop metastasis. If a patient has extraprostatic or lymph node-positive
disease at treatment, they transition to NRFT with probability 0.468 (defined as
pnc in Table 3.1), and they transition to PRFT with probability 0.532 (Roehl et al.
(2004)). The annual metastasis rate for patients in PRFT is 0.006 based on the
Mayo Clinic Radical Prostatectomy Registry (defined as g in Table 3.1) as used
in a previous prostate cancer model (Zhang et al. (2012a)). If a patient’s Gleason
score was upgraded as a result of a surveillance biopsy, they were assumed to have a
radical prostatectomy. From the post-diagnosis states patients eventually transition
to metastasis and/or death from prostate cancer or other causes.
Proportion of patients detected with GS < 7 who undergo active surveil-
lance (s); We estimated the mean probability that low-risk patients initiate active
surveillance to be 0.485 based on the logistic regression model presented in Liu et al.
(2015).
QALY Disutilities; The QALY disutility values were all obtained from Heijns-
dijk et al. (2012). As an example calculation, Heijnsdijk et al. (2012) reported a 0.9
utility for 3 weeks following a prostate biopsy. This is equivalent to a 0.9 utility for
3 weeks, and a 1.0 utility for the remaining 49 weeks of the year. Thus, the annual






and the QALY disutility for the year is 1 − 0.99423 = 0.00577. We calculated the
other disutilities using the same technique. The disutility for living with metastasis
is based on the disutility of palliative therapy presented in Heijnsdijk et al. (2012).
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3.2.2 Prostate Cancer Screening
The structure of the two-stage biomarker screening strategy is illustrated in Fig-
ure 3.2 in which two thresholds divide PSA values into low, intermediate, and high.
A patient receives a biopsy if his PSA value is high (> 10 ng/mL). If his PSA value is
low at a given screening age, then no biopsy is recommended. If the PSA is between
the low and high thresholds, then a second biomarker test is employed. If the second
biomarker test is positive, the patient receives a biopsy; otherwise, the patient does
not receive a biopsy and continues to be screened in future years. We evaluated two
PSA thresholds to trigger a second biomarker test: 2 and 4 ng/mL. We selected these
thresholds because it has been reported that phi, 4Kscore, and [-2] proPSA have the
ability to select men with PSA values of 2-10 ng/mL for prostate biopsy, and because
4 ng/mL is a commonly used biopsy threshold (Bratt and Lilja (2015)). We chose to
use this two-stage screening strategy for multiple reasons. First, PSA is an established
test and many new biomarkers are only approved to be used along with the PSA test.
Second, new biomarkers can be expensive, and this approach pragmatically uses the
new biomarkers when they will add greatest value and does not use them when they
have little value. Additionally, we assumed 100% adherence to the screening strategy
for our base case, and performed sensitivity analysis on the adherence rates.
We sampled PSA scores using a random effects model that includes the patient’s
current age and their age at onset of a preclinical tumor (Gulati et al. (2010)):
log{yi(t)} = β0i + β1it+ β2i(t− toi)I(t > toi) + ε,
where yi(t) is the PSA level for individual i at age t, t = 0 corresponds to age 35, toi
is the age at onset of a preclinical tumor for individual i, I is an indicator function,
and ε is random noise. Finally, individual intercepts and slopes for each individual i
are given by βki ∼ N(µk, σ2k) for k = 0, 1, 2.
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Figure 3.2: Two-stage biomarker screening strategy where the result of the PSA test
determines whether a second biomarker is used. If a patient’s PSA score
is greater than 10 ng/mL, they will automatically receive a biopsy. B
represents the observed second biomarker result for the patient, x is the
PSA threshold to trigger a second biomarker test, and y is the threshold
for the second biomarker to trigger biopsy.
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Table 3.2: Biomarker sensitivities and specificities for all-cancer and high-grade can-
cer (Gleason score ≥ 7) reported in the literature. The sensitivities and
specificities for 4Kscore and the MiPS tests were calculated using data pre-
sented in Parekh et al. (2015) and from the study Tomlins et al. (2016),
respectively. These 14 tests were evaluated for two PSA thresholds (2
ng/mL and 4 ng/mL), resulting in 28 screening strategies. Blank entries
for thresholds indicate no threshold given in the source.
Biomarker Test Threshold Sensitivity Specificity Source
All-cancer
% p2PS ≥ 1.7 0.70 0.70 Ferro et al. (2012)
% p2PS ≥ 2.5 0.38 0.90 Ferro et al. (2012)
phi ≥ 38.7 0.85 0.61 Ferro et al. (2012)
PCA3 − 0.93 0.37 Salami et al. (2013)
T2:ERG − 0.67 0.87 Salami et al. (2013)
T2:ERG − 0.37 0.93 Sartori and Chan (2014)
High-grade cancer
4Kscore ≥ 9% 0.90 0.52 Parekh et al. (2015)
4Kscore ≥ 12% 0.86 0.62 Parekh et al. (2015)
4Kscore ≥ 15% 0.79 0.70 Parekh et al. (2015)
All-cancer MiPS ≥ 25% 0.94 0.41 Tomlins et al. (2016)
All-cancer MiPS ≥ 52% 0.68 0.78 Tomlins et al. (2016)
High-grade MiPS ≥ 10% 0.95 0.36 Tomlins et al. (2016)
High-grade MiPS ≥ 15% 0.88 0.55 Tomlins et al. (2016)
High-grade MiPS ≥ 26% 0.70 0.76 Tomlins et al. (2016)
For the sensitivity and specificity of the second biomarker test, we used values re-
ported in the literature. We performed a systematic review of the literature and chose
the sensitivities and specificities that were non-dominated (i.e., biomarkers such that
no other biomarker had both a higher sensitivity and a higher specificity). Table 3.2
shows sensitivity and specificity values we used for all-cancer and high-grade cancer
(Gleason score ≥ 7). These 14 (second-stage) tests were evaluated for two (first-stage)
PSA thresholds (2 ng/mL and 4 ng/mL), resulting in 28 screening strategies. Biopsy
results were randomly sampled as either positive or negative, assuming a sensitiv-
ity of 0.8 (Haas et al. (2007)). If the biopsy result was positive, we estimated the
probability that the biopsy provides an incorrect grading at diagnosis based on data
reported in Epstein et al. (2012).
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3.2.3 Clinical Detection of Prostate Cancer
Patients were diagnosed with prostate cancer in one of two ways: by routine
screening (i.e., an elevated biomarker score that leads to a positive biopsy) or by
clinical detection (i.e., prostate cancer that develops symptoms). We assumed that
the lead time clock for clinical detection starts once a patient has both prostate
cancer and a PSA score ≥ 3 ng/mL. Savage et al. (2010) developed a distribution
of lead times from an elevated PSA measurement of ≥ 3 ng/mL to clinical diagnosis
of prostate cancer. For each patient, we randomly sampled a lead time from this
distribution. If a patient’s lead time is x years, after the patient has had prostate
cancer and a PSA score ≥ 3 ng/mL for x years, if the patient is alive and has neither
been diagnosed nor treated for prostate cancer, then the patient is assumed to be
clinically detected.
3.2.4 Prostate Cancer Treatment
Following diagnosis, patients received watchful waiting, active surveillance or rad-
ical prostatectomy. We assumed patients with Gleason score ≥ 7 received radical
prostatectomy. Patients diagnosed with Gleason score < 7 were assumed to be treated
via active surveillance or radical prostatectomy. Based on practice patterns reported
in Liu et al. (2015), we assumed that 48.5% of patients diagnosed with Gleason score
< 7 received active surveillance, while the other 51.5% received radical prostatec-
tomy. Given the lack of consensus in published guidelines for active surveillance, we
assumed that patients received a biopsy one year after diagnosis, followed by a biopsy
every two years for 10 years following diagnosis (Cooperberg et al. (2011)). Patients
over age 80 were assumed to receive watchful waiting.
Patients receiving active surveillance continue to progress through the natural
history of the disease until they have a biopsy result of Gleason score ≥ 7. We made
the same assumptions about surveillance biopsies as described above. If a patient’s
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Gleason score was upgraded as a result of a surveillance biopsy, they were assumed
to have a radical prostatectomy. However, if they are never detected to have higher
risk disease, they have the survival of an untreated patient. Survival following radical
prostatectomy depends on the stage of the disease at treatment. There are two
post-treatment states patients can transition to following treatment: no recurrence
following treatment (NRFT), and possible recurrence following treatment (PRFT).
If a patient has organ-confined disease at surgery, they transition directly to NRFT.
If a patient has extraprostatic or lymph node-positive disease at treatment, they
transition to NRFT with probability 0.468 (defined as pnc in Table 3.1), and they
transition to PRFT with probability 0.532. The annual metastasis rate for patients
in PRFT is 0.006 based on the Mayo Clinic Radical Prostatectomy Registry (defined
as g in Table 3.1). From the post-diagnosis states patients eventually transition to
metastasis and/or death from prostate cancer or other causes.
3.2.5 Model Validation
To perform model validation, we compared estimates of clinical statistics from our
model with literature estimates. The model estimates were based on the assumption
that all men were screened annually from age 50 to 75 with a PSA threshold of 4
ng/mL, because that was a common strategy at the time upon which the literature
estimates are based (Ross et al. (2000); Andriole et al. (2009)). We compared our
model results with independent estimates from the literature for age-dependent risks
of prostate cancer death, expected lifespan for a 40-year-old man, age-dependent risks
of prostate cancer diagnosis, Gleason score distribution at diagnosis, and biopsy-
detectable prostate cancer prevalence rates by age.
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3.2.6 Simulation Parameters
The AUA recommends shared decision-making for men considering PSA-based
screening from ages 55 to 69 with a screening interval of two years. Based on this rec-
ommendation, patients were PSA-screened every two years from ages 55 to 69 (Carter
et al. (2013)). Each patient simulation began at age 40. The model was used to eval-
uate 28 different prostate cancer screening strategies based on published estimates of
sensitivity and specificity for biomarkers reported in the literature. Table 3.2 shows
the sensitivity and specificity values for all cancer and high-grade cancer (Gleason
score ≥ 7). We compared these values with using PSA alone and to hypothetical
perfect biomarkers that have a sensitivity and specificity of 1.0 for either all cancer or
high-grade cancer. We also investigated the trade-off of sensitivity and specificity by
evaluating long-term health outcomes for patients under 30 different thresholds for
the high-grade MiPS test. To perform this analysis, we used a large data set of PSA,
PCA3, and T2:ERG scores from a presumed cancer-free population of patients under-
going diagnostic prostate biopsy to estimate the high-grade sensitivity and specificity
of the high-grade MiPS test under each threshold (Tomlins et al. (2016)).
For each strategy evaluated, we estimated the mean number of screening biopsies
and prostate cancer deaths per 1000 men, and the mean QALYs gained per 1000
men relative to no screening. Our QALY measurements account for disutilities of
screening, biopsy, diagnosis, active surveillance, radical prostatectomy, recovery from
radical prostatectomy, and metastasis; the values of the disutilities with their sources
are shown in Table 3.1. The reward update function for QALYs was:
rt(st, at) = 1− δScr(at)− δBiop(at)− δDia(at)− δTre(at)− δRec(at)− δAS(at)− δMet(st)
where rt(st, at) is the reward a patient receives at age t, which is 1 minus the disutilities
associated with screening, biopsy, diagnosis, treatment and the presence of metastatic
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cancer, as defined in Table 3.1. The arguments for the reward are the health state, st,
that defines the cancer status of the patient and the action, at, that defines whether a
screening test or biopsy was performed. The total expected QALYs a patient receives








where T denotes maximum lifespan and the expectation is with respect to the stochas-
tic process induced by the screening strategy π that defines the frequency of testing
and the thresholds at which to perform biomarker tests and/or biopsies. This amounts
to assuming a risk neutral decision maker (e.g. the patient). Since we are not analyz-
ing costs, we did not use a discount factor. Since exact evaluation of R in equation 3.1
is not straight-forward due to history dependence of rewards up to a given decision
epoch t, we used forward simulations to obtain statistical estimates based on N pa-










t (st, at) (3.2)
We synchronize patient histories using the method of common random numbers. Each
patient has his own stream of random numbers to determine his sequence of health
states and test results. This approach allows our model to compare a patient’s “nat-
ural history” of prostate cancer in the absence of screening to their health outcomes
under several screening approaches.
Simulation was performed to generate sample paths and obtain statistical esti-
mates of expected rewards for each strategy. This simulation model was implemented
in C/C++. We ran each strategy for 30,000,000 sample paths, which took less than
12.5 minutes to run using 3.40 GHz with 16 GB of RAM. The largest 95% confi-




We performed one-way sensitivity analysis on all of the model parameters by esti-
mating R̂ for varying choices of each parameter from a low to a high value, as defined
in Table 3.1. We also performed probabilistic sensitivity analysis, during which we
varied each model parameter by sampling from a uniform distribution between the
low and high values reported in Table 3.1. During the probabilistic sensitivity analy-
sis, we performed 30 experiments with 30,000,000 sample paths for each experiment.
Additionally, we looked at the impact of varying screening adherence (i.e., partici-
pation and attendance rates). We looked at the effect of varying these parameters
on the expected number of prostate cancer deaths per 1000 men and the increase in
QALYs per 1000 men relative to no screening. To perform sensitivity analysis, we
used the strategy with a PSA threshold of 2 ng/mL and a second biomarker test with
a high-grade sensitivity and specificity of 0.86 and 0.62, respectively.
3.3 Results
3.3.1 Model Validation
Table 3.3 compares estimates of clinical statistics from our model with literature
estimates from external validation studies. Overall, our estimates from the model
compare well with estimates from the literature. The SEER estimates that we have
compared to in Table 3.3 are from the years 2006 to 2008 (Howlader et al. (2012)).
Any variations are most likely due to our assumption that patients have perfect
adherence to the screening strategy.
Table 3.4 presents validation results in the absence of screening. Compared to
Table 3.3, the risk of prostate cancer death is higher, expected lifespan is lower, and
the Gleason score distribution at diagnosis shifts to higher grade disease. The risk
of diagnosis decreases for younger ages. After age 80, patients with advanced stage
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Table 3.3: Results from validation of the Monte Carlo simulation model based on the
partially observable Markov chain. The model estimates were based on the
assumption that all men were screened for prostate cancer (PCa) annually
from age 50 to 75 with a PSA threshold of 4 ng/mL.
Statistic Model Estimate Literature Estimate Literature Source
Overall risk of PCa death for
40-year-old man
2.73% 2.73% Howlader et al. (2012)
Age-dependent risk of PCa death Age Risk Age Risk
50 2.82% 50 2.82%
60 2.98% 60 2.98% Howlader et al. (2012)
70 3.18% 70 3.18%
80 3.36% 80 3.36%
Expected lifespan for 40-year-old
man (yr.)
38.19 37.7 Arias (2010)
Overall diagnosis risk for
40-year-old man
16.5% 16.6% Howlader et al. (2012)
Age-dependent risk of being Age Risk Age Risk
diagnosed with PCa within 10 50 3.1% 50 2.3%
years 60 6.1% 60 6.6% Howlader et al. (2012)
70 7.0% 70 8.2%
80 7.3% 80 5.1%
Gleason score (GS) distribution GS Proportion GS Proportion
at diagnosis < 7 53% < 7 49%
= 7 31% = 7 29% Draisma et al. (2003)
> 7 16% > 7 22%
Biopsy-detectable PCa Age Prevalence Age Prevalence
prevalence 50 13% 50 13%
60 22% 60 22% Haas et al. (2007)
70 36% 70 36%
80 50% 80 51%
disease present with symptoms or develop metastasis, which leads to a large number
of delayed diagnoses.
3.3.2 Base Case Analysis
We estimated the expected number of QALYs gained per 1000 men relative to no
screening for each of the biomarkers defined in Table 3.2 as well as two hypothetical
perfect biomarkers. Ten of the new biomarkers maximized expected QALY gains with
overlapping confidence intervals. The performance outcomes for these ten biomarkers
are shown in Table 3.5 along with the results for the hypothetical perfect biomarkers.
While there was no statistically significant difference between these ten tests in the
QALYs gained per 1000 men, the number of biopsies per 1000 men varied from 184 to
237. These ten tests also performed significantly better than using PSA alone with a
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Table 3.4: Results of the Monte Carlo simulation model based on the partially ob-
servable Markov chain for the case of no screening for prostate cancer
(PCa).
Statistic Model Estimate
Overall risk of PCa death for
40-year-old man
3.23%





Expected lifespan for 40-year-old
man (yr.)
38.15
Overall diagnosis risk for
40-year-old man
12.0%
Age-dependent risk of being Age Risk




Gleason score (GS) distribution GS Proportion
at diagnosis < 7 39%
= 7 34%
> 7 27%






Table 3.5: Best performing strategies in terms of QALYs gained per 1000 men com-
pared to no screening. Each strategy has a PSA threshold of 2 ng/mL to
trigger a second biomarker test, and assumes a biopsy will automatically
be performed on any patient with a PSA ≥ 10 ng/mL.
Second Biomarker Expected QALYs
gained per 1000 men
Number of screening
biopsies per 1000 men
Number of PCa deaths
per 1000 menTest Threshold Sensitivity Specificity
Perfect: HG * − 1.00 1.00 21.04 128.2 27.5
4Kscore * ≥ 12% 0.86 0.62 18.59 211.9 27.7
4Kscore * ≥ 15% 0.79 0.70 18.52 200.2 27.8
4Kscore * ≥ 9% 0.90 0.52 18.51 222.6 27.6
HG MiPS * ≥ 15% 0.88 0.55 18.48 219.6 27.7
MiPS * ≥ 25% 0.94 0.41 18.38 231.7 27.6
HG MiPS * ≥ 10% 0.95 0.36 18.30 235.0 27.6
Perfect: all − 1.00 1.00 18.01 146.5 27.1
HG MiPS * ≥ 26% 0.70 0.76 17.93 188.4 27.9
MiPS * ≥ 52% 0.68 0.78 17.79 184.2 28.0
PSA alone − − − 17.75 251.7 27.5
PCA3 − 0.93 0.37 17.65 236.9 27.6
phi ≥ 38.7 0.85 0.61 17.46 218.7 27.6
PCa = prostate cancer; QALYs = quality-adjusted life years.
* Sensitivity and specificity to high-grade (HG) prostate cancer (GS ≥ 7).
threshold of 4 ng/mL, achieving between 55% and 65% more QALYs gained per 1000
men. In terms of the initial PSA threshold to trigger a second biomarker test, a PSA
threshold of 2 ng/mL performed significantly better than 4 ng/mL in all two-stage
strategies, where using an initial PSA threshold of 2 ng/mL achieved between 55%
and 65% more QALYs gained per 1000 men than using an initial PSA threshold of 4
ng/mL.
Table 3.6 presents the expected QALYs gained per 1000 men, the number of
screening biopsies, and the number of prostate cancer deaths per 1000 men for each
of the screening strategies we evaluated. An initial PSA threshold of 2 ng/mL results
in more expected QALYs and fewer prostate cancer deaths compared to an initial





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.3 provides results for the number of screening biopsies and prostate can-
cer deaths per 1000 men. The figure displays tests from the literature that were
on the efficient frontier (i.e., any strategy that resulted in more biopsies and more
prostate cancer deaths than another strategy was removed), in addition to the perfect
biomarkers and using PSA alone. Figure 3.3 shows the trade-off that occurs between
minimizing prostate cancer deaths and minimizing the number of screening biopsies.
Although a PSA threshold of 4 ng/mL resulted in fewer biopsies, it also resulted in
more prostate cancer deaths. For example, consider the strategy with a PSA thresh-
old of 4 ng/mL and a second biomarker test with a sensitivity and specificity of 0.67
and 0.87 compared to the same strategy with a PSA threshold of 2 ng/mL. The latter
strategy is more aggressive, and thus reduces prostate cancer deaths by 6% compared
to the former strategy; however, it increases the number of screening biopsies being
performed by 49%. As expected, screening strategies with higher sensitivity resulted
in fewer prostate cancer deaths and more biopsies, while strategies with higher speci-
ficity resulted in fewer biopsies and more prostate cancer deaths. The only two tests
that maximized QALYs and also appeared on the efficient frontier of Figure 3.3 was
using PSA alone with a threshold of 2 ng/mL and the phi test with threshold of
38.7. Intuitively, using PSA alone with a threshold of 2 ng/mL minimized prostate
cancer deaths. The screening strategy that used a PSA threshold of 2 ng/mL and
a second biomarker test with high-grade sensitivity and specificity of 0.86 and 0.62,
respectively, maximized QALYs, and resulted in a prostate cancer death rate within
1% of using PSA alone with a threshold of 2 ng/mL, while reducing the number of
biopsies by 20%.
In addition to the efficient frontier of tests, Figure 3.3 also shows the results
for using PSA alone and for hypothetical biomarkers with perfect sensitivity and
specificity to all cancer and to high-grade cancer. There exists a two-stage biomarker
strategy that can simultaneously reduce the number of prostate cancer deaths and
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Figure 3.3: Estimated number of prostate cancer (PCa) deaths and screening biopsies
per 1000 men from modeled screening strategies. Each point on the graph
represents a different screening strategy and is labeled with the sensitivity
and specificity of the second biomarker. An asterisk (*) indicates that
the sensitivity and specificity are for high-grade prostate cancer (Gleason
score ≥ 7). This graph only displays the nondominated strategies of each
strategy type, i.e., strategies such that no other strategy resulted in both
a lower number of screening biopsies and a lower number of PCa deaths
per 1000 men screened (with the exception of the hypothetical perfect
biomarkers and PSA alone, which have been shown for reference). The
largest 95% confidence interval reflecting Monte Carlo error was less than
1% of the corresponding sample-mean point estimate.
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the number of screening biopsies compared to using PSA alone with a threshold of 4
ng/mL. In particular, using a PSA threshold of 2 followed by a test with sensitivity
and specificity of 0.37 and 0.93, respectively, can reduce the number of prostate cancer
deaths by 2% and the number of screening biopsies by 7% compared to using PSA
alone with a threshold of 4 ng/mL. For both PSA thresholds, the test with perfect
sensitivity and specificity to high-grade cancer resulted in more prostate cancer deaths
but fewer biopsies compared to the test with perfect sensitivity and specificity to all
cancer. This further highlights the trade-off between these two competing objectives.
To further investigate the relationship between possible biomarker thresholds, the
subsequent sensitivities and specificities that they imply, and long-term health out-
comes, we evaluated 30 different thresholds for the high-grade MiPS test using the
logistic regression model presented in Tomlins et al. (2016); the thresholds we consid-
ered ranged from 6% to 35% risk of high-grade cancer on biopsy. Figure 3.4 shows the
relationship between the 30 MiPS thresholds, the resulting sensitivity and specificity
to high-grade disease, and the mean increase in QALYs per 1000 men compared to no
screening. The maximum QALY gain was achieved with a high-grade MiPS threshold
of 18% and a corresponding high-grade sensitivity and specificity of 0.83 and 0.63,
respectively. Figure 3.4 demonstrates that as specificity is increased and sensitivity
is decreased, the expected number of QALYs decreases, which indicates that it is im-
portant to maximize sensitivity to high-grade disease in order to maximize expected
QALYs. The dotted lines show the 95% confidence interval, showing that thresholds
6− 29% have confidence intervals that overlap with the maximum achieved at 18%.
There is no statistically significant difference in QALYs gained and prostate cancer
deaths between the strategies with thresholds from 6% to 22%; however, the number
of screening biopsies per 1000 men ranged from 200 to 244. Thus, by looking at
performance outcomes in addition to QALYs, we can distinguish between strategies
that perform equally well in terms of QALYs.
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Figure 3.4: The relationship between sensitivity and specificity and their effect on
the performance of the screening strategy for a range of high-grade (HG)
MiPS thresholds to trigger biopsy. The performance of each threshold is
assessed by calculating expected QALYs gained per 1000 men compared
to no screening. Each of these strategies uses a PSA threshold of 2 ng/mL
to trigger a high-grade MiPS test. The maximum QALY gain is achieved
at a threshold of 18.
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3.3.3 Sensitivity Analysis
We performed one-way and probabilistic sensitivity analysis on the screening strat-
egy that maximized expected QALYs, which has a PSA threshold of 2 ng/mL and a
second biomarker test with a high-grade sensitivity and specificity of 0.86 and 0.62,
respectively. Using the base case parameter values, this 4Kscore strategy resulted in
27.7 prostate cancer deaths, 212 screening biopsies, and a gain of 19 QALYs per 1000
men. Additionally, we evaluated the impact of low screening adherence rates.
One-Way Sensitivity Analysis; One-way sensitivity analysis results are shown
in Figure 3.5, which is a tornado diagram that displays the effect each parameter
has on the expected increase in QALYs. The two parameters that had the greatest
effect on expected gain in QALYs were dt, the annual other-cause mortality rate, and
δRec, the annual QALY disutility for the 9-year post-radical prostatectomy recovery
period.
Figure 3.6 presents the one-way sensitivity analysis on the number of prostate
cancer deaths per 1000 men. The two parameters that had the greatest effect on the
prostate cancer mortality rate were: dt, the annual other-cause mortality rate, and
wt, the annual transition rate from No PCa to GS < 7 PCa, suggesting that patient
groups that have a higher risk of developing prostate cancer (e.g. African Americans
and patients with a family history) will be more likely to benefit from screening.
The parameter that had the greatest effect on both mean gain in QALYs and mean
number of prostate cancer deaths was dt, the annual other-cause mortality rate. When
the low and high values of the annual other-cause mortality rate are used, the increase
in QALYs per 1000 men ranged from 8 to 35 relative to the base case value of 19
QALYs, and the expected number of prostate cancer deaths per 1000 men ranged
from 22.4 to 35.5 relative to the base case value of 27.7. This suggests that patients
with comorbidities that are likely to have an increased risk of other-cause mortality
may not receive as many benefits from screening.
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Figure 3.5: One-way sensitivity analysis on expected gain in quality-adjusted life
years (QALYs) per 1000 men relative to no screening. The model pa-
rameters that we varied are defined in Table 3.1.
Probabilistic Sensitivity Analysis; The probabilistic sensitivity analysis re-
sults are presented in Figure 3.7, which shows the number of screening biopsies versus
the number of prostate cancer deaths per 1000 men from 30 experiments. The num-
ber of prostate cancer deaths ranged from 19.2 to 33.8, while the number of screening
biopsies ranged from 196 to 215 per 1000 men.
Varying Adherence Rates; As mentioned previously, patient adherence to
screening is often imperfect. To analyze the impact of adherence, we varied screening
participation and attendance rates for the screening strategy that maximized ex-
pected QALYs, which has a PSA threshold of 2 ng/mL and a second biomarker test
with a high-grade sensitivity and specificity of 0.86 and 0.62, respectively. We de-
fined the participation rate as the proportion of patients that participate in screening.
This is particularly relevant to prostate cancer screening, because fewer patients are
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Figure 3.6: One-way sensitivity analysis on expected number of prostate cancer (PCa)
deaths per 1000 men relative to no screening. The model parameters that
we varied are defined in Table 3.1.
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Figure 3.7: Probabilistic sensitivity analysis on the expected number of prostate can-
cer (PCa) deaths and screening biopsies per 1000 men. The model pa-
rameters that we varied and their bounds are defined in Table 3.1. The
base case value on the figure is labeled, and the other points represent
the 30 experiments.
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Table 3.7: Strategy performance in terms of QALYS gained relative to no screen-
ing, number of screening biopsies, and number of prostate cancer (PCa)





gained per 1000 men
Number of screening
biopsies per 1000 men
Number of PCa
deaths per 1000 men
0.50 9.02 106.0 30.0
0.60 11.28 127.1 29.5
0.70 12.79 148.3 29.1
0.80 14.88 163.6 28.6
0.90 16.72 190.7 28.6
1.00 18.59 211.9 27.7
Table 3.8: Strategy performance in terms of QALYS gained relative to no screening,
number of screening biopsies, and number of prostate cancer (PCa) deaths




gained per 1000 men
Number of screening
biopsies per 1000 men
Number of PCa
deaths per 1000 men
0.50 15.94 163.5 28.6
0.60 16.67 177.2 28.3
0.70 17.22 188.3 28.1
0.80 17.97 197.5 28.0
0.90 18.18 205.3 27.8
1.00 18.59 211.9 27.7
participating in the screening process since the U.S. Preventive Services Task Force
recommended against prostate cancer screening. We define the attendance rate as
the probability that patients participate in screening in a particular year. We varied
each of these values from 50% to 100%.
Table 3.7 presents our results from varying the screening participation rate (i.e.
the proportion of the population that participates in screening), and Table 3.8 presents
our results from varying the screening attendance rate (i.e. the probability a patient
shows up for screening in a particular year). As suspected, as participation and atten-
dance rates increase, the QALY gains increases, the number of prostate cancer deaths
decrease, and the number of biopsies being performed increases. We found that par-




We developed and validated a new partially observable Markov model that con-
siders prostate cancer screening and treatment decisions for a cohort of men, starting
at age 40, through to end of life. We used this model to examine alternative choices of
two-stage biomarker-based screening strategies based on newly discovered biomark-
ers. The screening strategy with a PSA threshold of 2 ng/mL and a second biomarker
with high-grade sensitivity and specificity of 0.86 and 0.62, respectively, increased the
number of QALYs per 1000 men by 19 QALYs compared to no screening and by 7
QALYs compared to using the PSA test alone with a threshold of 4 ng/mL. Our
model predicts one prostate cancer death averted per 200 men screened, assuming
men were screened annually from age 50 to 75 with a PSA threshold of 4 ng/mL.
Gulati et al. (2011) reported similar findings with a number needed to screen between
186 and 220.
Two recent modeling studies also examined the use of new biomarkers for prostate
cancer screening. Birnbaum et al. (2015) and Heijnsdijk et al. (2016) evaluated the
use of PCA3 and phi, respectively. We build on this previous work by evaluating
many new biomarkers head-to-head in the same model, providing useful information
when choosing between the many new biomarkers available. Another key differ-
ence from both of these studies is that we evaluated how the trade-off in sensitivity
and specificity affects performance of new biomarkers, including hypothetical perfect
biomarkers that provide an upper bound on the potential benefits of new biomarkers.
Finally, we evaluated the biomarkers in the context of QALYs as well as prostate
cancer deaths and number of biopsies per 1000 men.
A related study, Merdan et al. (2015), that considered the use of PCA3 and
T2:ERG for repeat biopsy decisions found similarly significant reductions in the num-
ber of biopsies in this more specific context. We found that using an initial PSA
threshold with a high sensitivity (2 ng/mL) and a second biomarker that has a high
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sensitivity (between 0.68 and 0.95) and low to moderate specificity (between 0.36 and
0.78) to high-grade disease appears to maximize expected QALYs. Interestingly, high
specificity in the second biomarker test, which is concomitant with low sensitivity,
results in significant reduction in QALYs, but minimizes the number of screening
biopsies. In our model, there are two populations of prostate cancer patients: (1)
patients with low-grade disease (Gleason score 6), and (2) patients with high-grade
disease (Gleason score ≥ 7). Patients with low-grade disease are unlikely to die from
prostate cancer, and therefore, are unlikely to benefit from screening. Patients with
high-grade cancer are more likely to develop metastatic disease, which is very likely to
cause prostate cancer death. Thus, biomarker tests for high-grade cancer outperform
all-cancer biomarkers for two reasons: (1) they are more likely to detect high-grade
disease and prevent a prostate cancer death, and (2) these high-grade biomarkers re-
duce the number of biopsies for patients with low-grade disease reducing the burden
of screening on patients that are unlikely to benefit.
In our one-way sensitivity analysis, we found that other-cause mortality has the
greatest impact on the expected increase in QALYs relative to no screening, suggest-
ing that the presence of comorbidity is an important consideration when determining
the optimal prostate cancer screening strategy. We found that the results were most
sensitive to variation in the QALY disutilities and the metastasis rate for patients with
undiagnosed prostate cancer, and least sensitive to variation in transition probabili-
ties. In our probabilistic sensitivity analysis, the prostate cancer mortality rate was
more sensitive to variation in model parameters than the mean number of biopsies.
Many different screening strategies performed similarly in terms of QALYs; how-
ever, we have found that it is possible to distinguish these similar screening strategies
by looking at additional performance measures that may better account for patient
preferences. For example, some strategies that achieved similar QALYs varied sig-
nificantly in rates of biopsy and prostate cancer deaths, with reductions in prostate
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cancer deaths coming at the expense of a greater biopsy rate. This trade-off em-
phasizes the importance of a shared decision making approach to account for patient
preferences regarding risk of prostate cancer mortality and harms from biopsy.
The hypothetical biomarkers that perfectly detect all cancer and high-grade can-
cer performed significantly better than screening strategies based on sensitivities and
specificities reported in the literature. This suggests there may be potential for ad-
ditional gains from new biomarker discoveries. Interestingly, the high-grade hypo-
thetical perfect biomarker achieved similar rates of prostate cancer mortality when
compared to the perfect all cancer biomarker, while reducing the number of screening
biopsies patients are subjected to. These data suggest screening biomarkers with an
ability to detect high-grade cancers may reduce unnecessary biopsies.
Our study has some limitations based on assumptions used in the modeling pro-
cess. First, estimates of sensitivity and specificity for biomarkers can be dataset-
dependent, as the estimates come from different datasets and, therefore, may have
different biases; however, our analysis still provides useful insights into how the sen-
sitivity and specificity of biomarkers impact long-term health outcomes. Second, we
are not aware of any longitudinal studies of long-term health outcomes associated
with these new biomarkers. In the absence of data to support correlations between
disease status, risk of preclinical progression and recurrence, PSA levels, and new
biomarkers operating characteristics, we have assumed no explicit correlations. If
correlations exist, it could lead to biased results and conclusions. Lastly, we assumed
that each patient receives at most one screening biopsy in his life. About 7− 12% of
men undergoing biopsy have had a previous negative biopsy (Nguyen et al. (2010);
Thompson et al. (2006)); however, the majority of patients receive a single biopsy,
and cancers detected on second biopsy are typically less clinically significant. Since
our intent is to measure the public health impact of biomarker screening, we do not
believe this assumption significantly influenced our results.
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These limitations notwithstanding, a number of conclusions can be drawn from
this study. Identifying biomarkers and risk thresholds optimized for identification of
high-grade cancers has the greatest impact on measures of performance in the screen-
ing setting. Combining new biomarkers with PSA has the potential to reduce the
number of screening biopsies (thus decreasing overdiagnosis) and decrease the rate of
prostate cancer mortality. The sensitivity analysis suggests our conclusions are robust
with respect to plausible variation in model parameters. New biomarkers with risk
thresholds optimized for identification of high-grade cancer can reduce the number of
prostate cancer deaths compared to PSA alone, while also increasing quality-adjusted
survival. These results support prospective clinical-validation trials using rationally
selected thresholds in order to design more efficient strategies for the early detection
of prostate cancer. We have shown that two-stage biomarker screening strategies can
be beneficial for the early detection of prostate cancer and have provided a founda-




Cost Effectiveness of Magnetic Resonance (MR)
Imaging and Targeted MR/Ultrasound Fusion
Biopsy for Prostate Cancer Screening
4.1 Introduction
Concerns about the poor sensitivity and specificity of the PSA test have led to rec-
ommendations to discontinue prostate cancer screening in the United States (Moyer
(2012)). In Chapter III we discuss the potential use of new molecular biomarkers
in patients with elevated PSA to better select men for initial biopsy. MRI has re-
cently been proposed as another potential minimally invasive way to achieve early
detection of prostate cancer. MRI has higher sensitivity and specificity to high-grade
disease than the new biomarkers we evaluated in Chapter III. Additionally, MRI
could potentially reduce overtreatment by preferentially detecting intermediate- and
high-grade cancers (Siddiqui et al. (2015); Meng et al. (2016); Oberlin et al. (2016);
Siddiqui et al. (2016)); however, MRI is more costly than molecular biomarkers and
there is limited evidence for its effectiveness as an intermediate test in patients being
screened for prostate cancer. Moreover, there are multiple ways to use MRI in a
screening setting, and it is not clear which is best. For example, if an MRI does not
detect lesions suspicious for prostate cancer, either no biopsy or a standard biopsy
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(which randomly samples cores of tissue from the entire prostate gland) can be per-
formed. If an MRI detects suspicious lesions, a targeted MR/ultrasound fusion biopsy
(i.e. targeted fusion biopsy) can be performed in which the MR images are used with
real-time ultrasound to sample cores of tissue directly from suspicious lesions; alterna-
tively, a combined approach can be used in which both standard and targeted fusion
biopsies are performed during a single biopsy session. Since there are multiple ways
to implement MRI in a screening setting, the optimal clinical pathway is unknown.
We used a Markov model to evaluate the cost-effectiveness of MRI in a screening
setting. We used the model to predict outcomes for five screening strategies and
report the results on the basis of 1000 men. The frequency of screening for each
strategy was based on the AUA guideline for PSA screening (Carter et al. (2013)).
The first strategy employed standard biopsy for men with elevated PSA (> 4 ng/mL).
The other four strategies performed MRI on men with elevated PSA, and the results
were used to decide whether the men should be referred for no biopsy, standard
biopsy, targeted fusion biopsy, or combined (standard + targeted fusion) biopsy. We
estimated the number of deaths averted, QALYs, and total cost for each strategy.
Additionally, we estimated the incremental cost-effectiveness ratios (ICERs).
4.2 Model
We adapted the partially observable Markov model described in Chapter III to
estimate outcomes for five screening strategies that utilize MRI. We also updated the
annual metastasis rate based on the following estimates from the literature (Johansson
et al. (2004)), with 95% confidence intervals shown in parentheses:
et =

0.024 (0.016− 0.035), if t ≤ 70
0.015 (0.009− 0.026), if t ≥ 71
53
Table 4.1: Definitions of five screening strategies.
Screening strategy PSA > 4 ng/mL Positive MRI Negative MRI
1 Standard Biopsy - -
2 MRI Targeted Fusion Biopsy Standard Biopsy
3 MRI Targeted Fusion Biopsy No Biopsy
4 MRI Combined Biopsy Standard Biopsy
5 MRI Combined Biopsy No Biopsy
We adopted this revised model because estimates for QALYs gained from PSA screen-
ing validate well relative to another recent cost-effectiveness study of PSA screening
(Heijnsdijk et al. (2015)). For example, Heijnsdijk et al. (2015) reports that screening
from ages 55 to 69 with two-year intervals and a PSA threshold of 3 ng/mL with a
3.5% discount rate results in 83 life-years gained and 61 QALYs gained per 1000 men.
Under the same conditions, our model estimates 71 life-years gained and 59 QALYs
gained per 1000 men.
For each strategy, for simulation purposes we used 30,000,000 samples of biopsy-
näıve men who were screened every two years from age 55 to 69 according to the
AUA guideline. In strategy 1, a standard biopsy was recommended for elevated
PSA (> 4 ng/mL). The decision-rule diagram for strategies 2 through 5 is shown in
Figure 4.1. Each strategy recommended MRI for elevated PSA, while actions based
on the MRI results depended on the strategy as defined in Table 4.1. Our model
focuses on initial biopsy decisions; thus, the screening strategy terminates after the
patient receives an initial biopsy or two negative MRIs; however, the patient continues
to make state transitions in the absence of screening until all-other-cause mortality
or clinical detection and subsequent prostate cancer mortality.
The model was comprised of discrete health states based on Gleason score, which
are not directly observable, but can be inferred from PSA and/or MRI subject to
published estimates of sensitivity and specificity. For standard biopsy, the results
were randomly sampled as either positive or negative, assuming a sensitivity to any
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Figure 4.1: Decision rule diagram for screening strategies 2 through 5. All of the
decision rules were compared to no screening and the case of standard
biopsy for PSA greater than 4 ng/mL.
Table 4.2: Standard biopsy simulator based on data provided in Epstein et al. (2012).
Biopsy result
No cancer GS <7 GS = 7 GS >7
True health
state
No cancer 1.00 0.00 0.00 0.00
GS <7 0.20 0.71 0.08 0.00
GS = 7 0.20 0.32 0.43 0.04
GS >7 0.20 0.12 0.26 0.42
cancer of 0.8 (Haas et al. (2007)). If the biopsy result was positive, the probability
that the biopsy provides an incorrect grading at diagnosis was based on data reported
in Epstein et al. (2012). The exact standard biopsy data is provided in Table 4.2.
For targeted fusion and combined biopsy, we used the values of sensitivity and
specificity to high-grade cancer reported in Siddiqui et al. (2015): 0.77 and 0.68,
respectively, for targeted fusion biopsy, and 0.85 and 0.49, respectively, for combined
biopsy. Based on Medicare infection rates reported in Loeb et al. (2011), 1.1% of
biopsies performed led to hospitalization for post-biopsy infection (Gonzalez et al.
(2012)).
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As described in Chapter III, the model incorporated the clinical detection of symp-
tomatic prostate cancer in addition to detection of prostate cancer through routine
screening. For each patient, we randomly sampled a lead time from an elevated PSA
measurement of ≥ 3 ng/mL to clinical diagnosis of prostate cancer from a distribution
developed by Savage et al. (2010). After a patient had prostate cancer and a PSA
score ≥ 3 ng/mL for their lead time and had not yet been diagnosed with prostate
cancer, it was assumed the patient was clinically detected due to symptoms.
4.2.1 Treatment
In the updated model, patients with PSA > 20 ng/mL or a Gleason score ≥ 8
were assumed to receive a bone scan and a CT scan for staging (Merdan et al. (2014);
Risko et al. (2014)). As described in Chapter III, patients with a biopsy result
of Gleason score ≥ 7 received radical prostatectomy. Based on practice patterns
reported in Liu et al. (2015), we assumed that 48.5% of patients diagnosed with
Gleason score 6 prostate cancer received active surveillance, while the rest received
radical prostatectomy. If a patient was clinically detected to have prostate cancer
after age 80, we assumed they received watchful waiting. Men on active surveillance
received an annual PSA test and a biopsy every two years. For men with no indication
of progression, survival was consistent with survival for men with Gleason score 6
disease. If any biopsy indicated progression in Gleason score, the patient received
radical prostatectomy. Men treated via radical prostatectomy had survival consistent
with a treated population (Roehl et al. (2004)), with the potential for progression to
metastatic prostate cancer and prostate cancer mortality. Other-cause mortality was
based on estimates from CDC life tables (Arias (2010)).
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Table 4.3: Clinical interpretation of PI-RADS scores (Barentsz et al. (2012)).
PI-RADS score Clinical interpretation
1 Clinically significant disease is highly unlikely to be present
2 Clinically significant cancer is unlikely to be present
3 Clinically significant cancer is equivocal
4 Clinically significant cancer is likely to be present
5 Clinically significant cancer is highly likely to be present
4.2.2 PSA and MRI Sensitivity and Specificity
A published statistical model from the Prostate Cancer Prevention Trial was
used to sample age-dependent and cancer onset-dependent PSA scores (Gulati et al.
(2010)). The outcome of MRI was based on prostate imaging reporting and data
system (PI-RADS) scores, between 1 and 5, which are defined in Table 4.3 with an
increasing score indicating an increasing likelihood of the presence of clinically sig-
nificant cancer (Barentsz et al. (2012)). We considered two PI-RADS thresholds to
trigger biopsy: 3 and 4. A PI-RADS threshold of ≥ 3 had a sensitivity and speci-
ficity to clinically significant disease of 0.965 (95% CI: 0.868–0.994) and 0.597 (95%
CI: 0.512–0.677), respectively, and a PI-RADS threshold of ≥ 4 had sensitivity and
specificity values of 0.789 (95% CI: 0.658–0.882) and 0.789 (95% CI: 0.699–0.841),
respectively (Grey et al. (2015)). Table 4.4 reports the probability that MRI results
will be positive and negative for each threshold for a patient with no prostate cancer,
prostate cancer with a Gleason score < 7, and prostate cancer with a Gleason score
≥ 7. To calculate the values in Table 4.4, we extracted the data from Figure 2 of
Grey et al. (2015).
4.2.3 Costs and Quality of Life
For each combination of the five screening strategies and the two PI-RADS score
thresholds, we estimated the mean cost and the mean QALYs gained per 1000 men
relative to no screening. The values of the disutilities with their sources are shown
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Table 4.4: The probability of positive and negative MRI results for different PI-RADS
thresholds for no prostate cancer, Gleason score < 7 prostate cancer, and
Gleason score ≥ 7 prostate cancer (Grey et al. (2015)).
No prostate cancer Gleason score < 7 Gleason score ≥ 7
PI-RADS
threshold
P(+ MRI) P(− MRI) P(+ MRI) P(− MRI) P(+ MRI) P(− MRI)
≥ 3 0.387 0.613 0.525 0.475 0.967 0.033
≥ 4 0.204 0.796 0.311 0.689 0.796 0.204
in Table 4.5. Our assumptions were similar to those of previous studies (Aizer et al.
(2015); Roth et al. (2016); Heijnsdijk et al. (2012)). The post-recovery period for
radical prostatectomy was assumed to last 9 years (Heijnsdijk et al. (2012)). Li et al.
(2016) reported the disutility for hospitalization due to post-biopsy infection to be
0.28, which we assumed lasted for three weeks (Heijnsdijk et al. (2012)). Grann et al.
(2011) reported the disutility for MRI as 0.04, which we assumed lasted for one week
(Heijnsdijk et al. (2012)).
The reward update function for QALYs was:
qt(st, at) = 1−∆Scr(at)−∆MRI(at)−∆Biop(at)−∆Inf(at)−∆Dia(at)
−∆AS(at)−∆RP(at)−∆Rec(at)−∆Met(st)−∆Term(st)
(4.1)
where qt(st, at) is the reward a patient receives at age t, which is 1 minus the disutil-
ities associated with screening, MRI, biopsy, post-biopsy infection, diagnosis, active
surveillance, radical prostatectomy, recovery from radical prostatectomy, metastasis,
and terminal disease, as defined in Table 4.5. The arguments for the reward are the
health state, st, that defines the cancer status of the patient and the action, at, that
defines whether screening tests or biopsy was performed. Since we are also analyz-
ing costs, we used discount factor of 3%. Thus, the number of discounted QALYs a
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where T denotes maximum lifespan and the expectation is with respect to the stochas-
tic process induced by the screening strategy i that defines the screening pathway and
the thresholds at which to perform biopsies. Since exact evaluation of Qi in equa-
tion 4.3 is not straight-forward due to history dependence of rewards up to a given













Cost estimates with their sources are shown in Table 4.6. At each age, the cost
of prostate cancer screening and treatment, ct, is calculated. The discounted cost at
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Table 4.5: Annual disutilities for health states considered in our cost-effectiveness
analysis.
Health state Annual disutility (range) Source
PSA screnning 0.00019 (0.0–0.00019) Heijnsdijk et al. (2012)
MRI 0.00077 (0.00038–0.0012) Grann et al. (2011)
Heijnsdijk et al. (2012)
Biopsy 0.00577 (0.00346–0.0075) Heijnsdijk et al. (2012)
Post-biopsy infection 0.0161 (0.00969–0.0291) Li et al. (2016)
Heijnsdijk et al. (2012)
Diagnosis 0.0167 (0.0125–0.0208) Heijnsdijk et al. (2012)
Radical prostatectomy 0.247 (0.0917–0.323) Heijnsdijk et al. (2012)
Post-radical prostatectomy recovery 0.05 (0.0–0.07) Heijnsdijk et al. (2012)
Active surveillance 0.03 (0.0–0.15) Heijnsdijk et al. (2012)
Palliative therapy 0.4 (0.14–0.76) Heijnsdijk et al. (2012)
Terminal illness 0.3 (0.3–0.38) Heijnsdijk et al. (2012)
Table 4.6: Costs considered in our cost-effectiveness analysis. Costs from the litera-
ture have been updated to 2016 US dollars based on inflation.
Intervention Unit costs in $ Source
PSA screening 33.86 Medicare data
MRI 964.21 Medicare data
Standard prostate biopsy a 2,953.67 Medicare data
Targeted fusion prostate biopsy b 3,018.35 Medicare data
Combined prostate biopsy b 3,018.35 Medicare data
Post-biopsy infection-related hospitalization 6,361.31 Adibi et al. (2012)
Gonzalez et al. (2012)
Staging 1,059.28 Medicare data
Active surveillance – standard biopsy (per year) c 1,642.58 Medicare data
Active surveillance – targeted biopsy (per year) c 1,674.92 Medicare data
Active surveillance – combined biopsy (per year) c 1,674.92 Medicare data
Radical prostatectomy 15,752.37 Aizer et al. (2015)
Distant-stage initial treatment 17,831.29 Roth et al. (2016)
Distant-stage management (per year) 2,500.65 Roth et al. (2016)
Other cause of death 5,975.15 Mariotto et al. (2011)
Prostate cancer death (age < 65) 103,884.24 Mariotto et al. (2011)
Prostate cancer death (age ≥ 65) 69,256.16 Mariotto et al. (2011)
a Includes professional, technical, and facility fees, pathology costs, and office visit.
b Includes professional, technical, and facility fees, pathology costs, office visit, and 3D recon-
struction.
c Assumed to include an annual office visit, annual PSA test, and a biopsy every two years.
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4.2.4 Cost Effectiveness
Future costs and QALYs were discounted to net present value using an annual
discount rate of 3% (Shepard (1996)). Net costs per QALY gained were calculated
for strategies 1 through 5 relative to no screening as the incremental costs of the
screening strategy divided by the incremental QALYs of the screening strategy.
We identified the efficient strategies by removing dominated strategies (i.e., strate-
gies that are more expensive and less effective than another strategy) as well as strate-
gies ruled out by extended dominance (i.e., strategies that have higher ICERs than
a more effective strategy) (Shepard (1996)). The ICERs of the efficient policies were
calculated as the incremental costs divided by the incremental health gains compared




, where Qa > Qb. (4.8)
If the ICER is under $100,000/QALY, the screening strategy is considered cost-
effective (Neumann et al. (2014)).
4.2.5 Sensitivity Analysis
To evaluate the robustness of our results, we performed one-way sensitivity anal-
ysis on the ICER for the optimal screening strategy. Ranges of the QALY disutilities
appear in Table 4.5. Cost estimates and other-cause mortality rates (Arias (2010))
were varied by ±20%. The sensitivity and specificity of PI-RADS threshold 3 were
varied using the 95% confidence intervals reported in Grey et al. (2015). The annual
metastasis rate for patients with undiagnosed prostate cancer was varied within the
95% confidence interval reported in Johansson et al. (2004). Finally, we varied the
annual prostate cancer incidence rate within the 95% confidence interval reported
in Haas et al. (2007). Threshold analysis was also performed on the sensitivity and
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specificity of MRI and combined biopsy under the optimal strategy. Base case values
of the sensitivity and specificity of MRI were 0.965 and 0.597, respectively, and base
case values of the sensitivity and specificity of combined biopsy were 0.850 and 0.490,
respectively. During threshold analysis, we simultaneously reduced the sensitivity
and specificity of MRI and combined biopsy until it was no longer cost-effective to
use MRI for screening.
4.3 Results
4.3.1 Base Case Analysis
Table 4.7 presents the deaths averted, life-years and QALYs gained, the costs, and
cost-effectiveness estimates for each screening strategy. The largest 95% confidence
interval for QALY and cost per patient reflecting Monte Carlo statistical error was less
than 1% of the corresponding sample-mean point estimate. The net discounted costs
per QALY gained compared to no screening for each screening strategy was below
$100,000/QALY. Strategy 5 with a PI-RADS threshold of 3 maximized expected
QALYs and number of prostate cancer death averted, and had the lowest net cost
per QALY gained at $33,953/QALY.
Figure 4.2 compares the QALYs gained per 1000 men under a PI-RADS threshold
of 3 versus a PI-RADS threshold of 4. For each strategy, a PI-RADS threshold of 3
outperforms 4 in QALYs gained. Figure 4.3 shows the QALYs gained per 1000 men
when using a targeted fusion biopsy versus a combined biopsy after a positive MRI.
In each case, performing a combined biopsy after positive MRI resulted in additional
QALY gains compared to performing a targeted fusion biopsy.
Figure 4.4 shows the incremental effectiveness in QALYs versus the incremental
cost for each strategy relative to no screening. Dominated strategies were simultane-
ously more expensive and less effective than at least one other strategy. Interestingly,
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Table 4.7: Predicted effects, costs, and cost-effectiveness for various screening strate-












No screening - - - 12,413 -
Strategy 1 4.7 58.7 47.8 (47.2–48.3) 12,964 39,381
Strategy 2, PI-RADS≥ 3 5.2 64.1 53.0 (52.4 –53.5) 13,050 40,019
Strategy 2, PI-RADS≥ 4 5.1 63.0 51.9 (51.3 –52.5) 13,064 41,415
Strategy 3, PI-RADS≥ 3 5.2 64.3 53.9 (53.3 –54.5) 13,034 37,218
Strategy 3, PI-RADS≥ 4 4.9 60.3 50.9 (50.3 –51.4) 13,038 38,059
Strategy 4, PI-RADS≥ 3 5.8 71.4 59.2 (58.6 –59.8) 13,021 36,138
Strategy 4, PI-RADS≥ 4 5.5 68.7 56.8 (56.2 –57.5) 13,041 37,725
Strategy 5, PI-RADS≥ 3 5.9 72.6 60.7 (60.1 –61.3) 13,002 33,953
Strategy 5, PI-RADS≥ 4 5.5 67.8 57.2 (56.6 –57.8) 13,009 34,426
Effects and costs are shown without discount. Cost-effectiveness is calculated at 3% discount rate for costs and
QALYs. In 2016 US dollars. PCa = prostate cancer; QALY = quality-adjusted life year.
a Compared with no screening.
Figure 4.2: QALYs gained per 1000 men relative to no screening using a PI-RADS
threshold of 3 versus 4 for Strategies 2–5. Strategy 1 resulted in 47.8
QALYs gained per 1000 men. Screening strategies are defined in Ta-
ble 4.1. QALY = quality-adjusted life years; PI-RADS = prostate imag-
ing reporting and data system.
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Figure 4.3: QALYs gained per 1000 men relative to no screening using a targeted fu-
sion biopsy versus combined biopsy after positive MRI. Strategy 1 resulted
in 47.8 QALYs gained per 1000 men. Columns are labeled with the type
of biopsy performed after negative biopsy (no biopsy or standard biopsy)
and the PI-RADS threshold used to indicate a positive MRI. QALY =
quality-adjusted life years; PI-RADS = prostate imaging reporting and
data system.
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Figure 4.4: Incremental health benefits and costs associated with alternative screen-
ing strategies relative to no screening. Costs and QALYs are discounted
at a rate of 3%. Each point is labeled with the screening strategy and
PI-RADS threshold. Screening strategies are defined in Table 4.1. Lines
connecting points representing two efficient screening strategies indicate
the incremental cost-effectiveness ratio (ICER). QALY = quality-adjusted
life years; PI-RADS = prostate imaging reporting and data system.
all four schemas that performed a standard biopsy after a negative MRI (strategies
2 and 4, with PI-RADS thresholds of 3 or 4) were dominated by strategies that per-
formed no biopsy after negative MRI (strategies 3 and 5). The efficient strategies were
strategy 1, strategy 5 with PI-RADS threshold of 4 with an ICER of $14,031/QALY,
and strategy 5 with PI-RADS threshold of 3 with an ICER of $23,483/QALY. Thus,
we found strategy 5 (i.e., MRI if PSA > 4 ng/mL, combined biopsy if MRI posi-
tive, no biopsy if MRI negative) with PI-RADS threshold of 3 to be optimal under a
willingness-to-pay threshold of $100,000/QALY.
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4.3.2 Sensitivity Analysis
Figure 4.5 shows the one-way sensitivity analysis on the net costs per QALY
gained relative to no screening for strategy 5 with a PI-RADS threshold of 3. We
performed one-way sensitivity analysis on all model parameters; Figure 4.5 shows the
parameters that varied the net costs per QALY gained by at least $5,000/QALY when
using the low and high values. The three model parameters that had the greatest
impact were: (1) the metastasis rate for undiagnosed prostate cancer; (2) the annual
QALY disutility for the 9-year post-radical prostatectomy recovery period; and (3)
the annual QALY disutility for living with metastasis. In the sensitivity analysis,
the only scenario that is not cost-effective under a willingness-to-pay threshold of
$100,000/QALY is a patient with a very low risk of developing metastasis, suggesting
that our results are robust for most patients and cost-effective under a willingness-
to-pay threshold of $100,000/QALY. Threshold analysis shows that strategy 5 with
a PI-RADS threshold of 3 remains cost-effective under a willingness-to-pay threshold
of $100,000/QALY when sensitivity and specificity of MRI and combined biopsy
to high-grade cancer are all simultaneously reduced by 0.19. In particular, it is
still cost-effective when sensitivity and specificity of MRI are ≥ 0.775 and ≥ 0.407,
respectively, and sensitivity and specificity of combined biopsy are ≥ 0.660 and ≥
0.300, respectively.
4.4 Conclusions
Based on our study, MRI as an intermediate test in the screening of men for
prostate cancer is cost-effective assuming a willingness-to-pay threshold of $100,000/
QALY threshold. The optimal strategy was the use of MRI if PSA > 4 ng/mL,
followed by combined biopsy if MRI was positive and no biopsy if MRI was negative,
using a PI-RADS threshold of 3 to indicate a positive MRI. These results were robust
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Figure 4.5: Tornado diagram of one-way sensitivity analysis on the net costs per
QALY gained of strategy 5 with a PI-RADS threshold of 3 relative to
no screening. Costs and QALYs are discounted at a rate of 3%. RP =
radical prostatectomy; PCa = prostate cancer.
over a range of sensitivity analyses and were maintained even if the sensitivity and
specificity of MRI and combined biopsy were reduced by 19 percentage points.
Although MRI has recently been proposed as an effective way to achieve early
detection of prostate cancer, evidence in support of the use of MRI for early detection
of prostate cancer in biopsy-näıve men is sparse. Ahmed et al. (2017) showed that MRI
could be effective from a clinical perspective by reducing primary biopsy and clinically
insignificant cancer diagnoses, but did not consider the cost-effectiveness. Willis et al.
(2014) performed clinical decision analysis and de Rooij et al. (2014) performed cost-
effectiveness analysis; however, both studies assumed a fixed sensitivity and specificity
of MRI and assumed that positive MRI is automatically followed by a targeted fusion
biopsy, while negative MRI automatically results in no biopsy. Thus, they evaluated
one clinical pathway compared to the standard of care. Our study evaluated strategies
that performed targeted fusion biopsy or combined biopsy on positive MRI, as well
as the option to perform a standard biopsy or no biopsy on negative MRI. Thus, our
study evaluated eight MRI-based clinical pathways (two PI-RADS thresholds for each
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of the four MRI-based strategies) compared to screening with PSA alone, allowing us
to estimate the effects of varying PI-RADS thresholds and biopsy techniques on the
cost-effectiveness of using MRI for prostate cancer screening.
Additionally, our study focuses on long-term costs and health outcomes over the
patient’s entire lifetime, rather than assessing short-term outcomes. Including long-
term costs and health impacts enabled us to assess the potentially negative impact of
detecting low-risk cancers related to harm from biopsy(-ies) and overtreatment. Prior
studies did not account for the costs and harms associated with biopsy complications,
resulting in an overestimation of the benefit from screening and an underestimation
of the costs.
Heijnsdijk et al. (2015) evaluated the cost-effectiveness of several PSA screening
policies in the absence of MRI, and our models produced similar expected outcomes
for PSA screening. The net cost per QALY gained we present for PSA screening is
lower than the results reported in Heijnsdijk et al. (2015) because we include more
costs in our model, including the significant cost of a prostate cancer-related death.
Using MRI for prostate cancer screening resulted in health benefits for the patient
compared to both no screening and screening using PSA alone. For example, the
screening strategy where men with a PI-RADS score ≥ 3 were recommended for
combined biopsy (i.e., strategy 5) resulted in 5.9 prostate cancer deaths averted, 60.7
QALYs gained, and 72.6 life-years gained per 1000 men compared to no screening.
For every screening strategy, a PI-RADS threshold of 3 outperformed a threshold of
4 in terms of QALYs, while also resulting in lower costs. Our results also suggest that
performing a combined biopsy after a positive MRI outperforms performing a targeted
fusion biopsy in terms of QALYs. However, there does not appear to be a benefit to
performing standard biopsy on negative MRI, because it results in additional costs
and disutility to the patient and overall does not provide sufficient health benefits.
This conclusion has been supported in the literature. For example, Hansen et al.
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(2016) concluded that biopsies may not be necessary for men with elevated PSA and
nonsuspicious MRI because the negative predictive value for excluding Gleason score
≥ 7 disease on MRI was very high. Our study adds additional evidence in support of
this conjecture.
Given the wide variability in the quality of radiology reporting and interpretation
of MRI results, we performed threshold analysis on the sensitivity and specificity of
MRI and combined biopsy. These analyses found this approach to be a cost-effective
method of early detection even if the sensitivity and specificity were substantially
lower than estimates reported in the literature, suggesting that our results may be
relevant in a community setting where sensitivity and specificity may be lower than
specialized medical centers where most previous MRI studies have been conducted.
Sensitivity analysis suggests our results are robust with respect to reasonable variation
of the model parameters; however, the results are sensitive to the annual metastasis
rate for an undiagnosed prostate cancer patient. Under the metastasis rate assump-
tion from Chapter III, MRI is not cost-effective when QALYs are discounted.
One potential limitation of our study is that there is the potential for bias in the
data we used to estimate MRI results because the population used includes patients
with previous negative biopsies in addition to biopsy-näıve patients; however, by us-
ing the estimates based on the larger patient population we were able to obtain better
estimates of sensitivity and specificity. Our sensitivity analysis further confirms our
conclusions are not sensitive to this assumption. Another possible limitation is the
inconsistent definition of clinically significant prostate cancer in the literature. For
example, Siddiqui et al. (2015) defined clinically significant disease as high-volume
Gleason 3+4, or Gleason ≥ 4 + 3, while Grey et al. (2015) defined clinically signifi-
cant disease to be cancer core involvement ≥ 6 mm or the presence of any Gleason
pattern 4. In our model, we considered clinically significant disease to be any Gleason
score ≥ 7. Additionally, the only curative treatment included in our model was rad-
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ical prostatectomy, because it is the most common curative treatment, and patients
undergoing radiation therapy have similar health outcomes (Hamdy et al. (2016)).
Finally, our model uses many different sources of data; however, given the long-term
evaluation period needed for prostate cancer screening, randomized trials are unlikely
to be able to assess long-term QALYs and costs. These limitations notwithstanding,
we believe this study provides important evidence in support of the use of MRI for
early detection of prostate cancer in biopsy-näıve men, both from a health benefit
and cost perspective.
Our results show that incorporating MRI into prostate cancer screening in biopsy-
näıve men is cost-effective under a willingness-to-pay threshold of $100,000/QALY.
The strategies that performed a standard biopsy on negative MRI were more expen-
sive and less effective than strategies that perform no biopsy on negative MRI. The
screening strategy where men with PI-RADS score ≥ 3 were recommended for com-
bined biopsy, while men with PI-RADS score< 3 were recommended for no biopsy was
optimal and cost-effective with an ICER of $23,483/QALY. Therefore MRI appears to
be a viable approach for early detection of prostate cancer from a cost-effectiveness
perspective. More analysis would need to be done to explore whether the use of
molecular biomarkers could also be cost-effective, since biomarkers are less expensive




Optimization of Biomarker-Based Screening
Policies
5.1 Introduction
The policies evaluated in Chapter III are myopic in the sense that they make
biopsy decisions based solely on a patient’s most recent test results, without con-
sidering the patient’s full medical history. However, benign conditions can cause a
sudden spike in a patient’s biomarker scores, which motivates the potential to use
Bayesian updating to estimate the belief state for patients so decisions can be made
based on estimates of patient risk of cancer, rather than biomarker scores. Thus, we
have extended the model of Chapter III to create a new POMDP model to investigate
optimal prostate cancer screening decisions based on a patient’s belief state, which
is calculated using Bayesian updating and comprises a patient’s complete history of
biomarker test results in a way that is similar to the model first proposed by Small-
wood and Sondik (1973). This POMDP can be used to determine how, if at all, new
biomarker tests should be used for prostate cancer screening. We present results for
the case of high-grade MiPS. We chose high grade MiPS because it was found to be
a good biomarker in Chapter III and because we had access to the data necessary
to estimate the probability distribution of MiPS conditional on the patient cancer
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status. However, the approach we lay out could be applied to other biomarkers and
in other disease contexts.
5.2 Model
We have developed a POMDP model that maximizes total expected QALYs by op-
timizing the decision to conduct a biopsy based on the patient’s belief state at annual
decision epochs. In this chapter, to be consistent with the literature on POMDPs we
will refer to the patient’s underlying health state as the core state of the patient. The
set of core states and the one-step transition probability matrix are the same as defined
in Chapter III: S = {NC, OCG1, OCG2, OCG3, EPLN, PRFT, NRFT, M, D}.
At each decision epoch from ages t = 1, . . . , T , we assume a high-grade MiPS
test is performed. The set of actions is A = {Wait, Biopsy}, i.e. wait until the
next decision epoch or perform a biopsy. The observations that result from the high-
grade MiPS test inform the action. The observation space for the high-grade MiPS
test are continuous values between 0 and 1; however, to simplify the problem we
discretized these observations into clinically relevant bins. The set of observations is
Θ, which includes the MiPS discretized observations in addition to Post-treatment
(PT), Metastasis (M), Death (D). The observations for the action “Biopsy” are NC,
OCG1, OCG2, and OCG3. Since only a small amount of tissue is sampled during a
biopsy, sampling error can result in a false negative or incorrect grading at diagnosis.
Based on the discretization of the MiPS test results, we have developed information
matrices by age, Qt, t = 55, . . . , 69. The information matrix has rows associated with
the core health states and columns associated with the set of possible observations.
We denote the components of each information matrix by qt(θ|st), which defines the
probability of observing θ ∈ Θ at age t given the core state of the patient is st ∈ S.
In the following description of the model we use notation consistent with the
notation used in Smallwood and Sondik (1973). Let πt = [πt1, π
t
2, . . . , π
t
9] be the belief
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vector, where πti is the probability that the patient is in state i at decision epoch t and∑
i π
t
i = 1. The belief vector is updated via Bayesian updating after the observations














where q(θ|j) denotes the probability of observing θ, given the core state of the patient
is j. The numerator calculates the probability of transitioning to state j and observing
output θ, and the denominator is the probability of observing output θ. This is an
application of Bayes law, and the equation is developed in detail in Appendix A of
Smallwood and Sondik (1973).













, t = 1, ..., T − 1
VT (π
T ) = R(πT )
where r(πt, a, πt+1) is the immediate reward in QALYs and Vt(j) is the maximum
expected future QALYs for a patient in state j at age t.
5.3 Methods
The terminal reward vector, αT , consists of the expected QALYs for a patient at
age 70 in each core state. The infinite state space of a POMDP makes it difficult to
solve. Thus, we have divided the space into a fixed-finite grid, which allows us to




i = 1}, with a finite grid of points.
By discretizing the belief space, we can associate every sampled belief state with one
of the grid points (e.g. based on the closest grid point). Thus, the continuously
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sampled states are mapped to a finite set of states.
At any given decision epoch, we know that the patient will be in one of three
subsets of the state space: S1 = {NC, OCG1, OCG2, OCG3, EPLN}, S2 = {PRFT,
NRFT}, or S3 = {M, D}. The set S1 includes the unobservable pre-diagnosis states,
S2 includes the unobservable post-treatment states, and S3 includes the observable
states. In other words, if a patient has not yet been diagnosed with prostate cancer,
we know that they are in one of the five states in S1; if a patient has been treated
for prostate cancer, we know they are in one of the post-treatment states in S2; and
we know the exact state of the patient when they are in the completely observable
S3. Therefore, any grid point in the discretized state space we generate will have
non-zero entries in only one of the three subsets. The grid points in S3 will consist of
(0, 0, 0, 0, 0, 0, 0, 1, 0) and (0, 0, 0, 0, 0, 0, 0, 0, 1), i.e., the states in S3 are
perfectly observable.
We utilized a data-driven sampling approach to develop the grid at each age. We
denote a sample path to be the stochastic progression of a patient’s health states,
biomarker test results, biopsy results, and belief states. A patient’s sample path
depends on the screening strategy being used. For this reason, we generated sample
paths using varying policies. The sample paths provided information about not only
where patients’ beliefs are located in the belief space at each age, but also information
about where a patient’s belief’s are not located in the belief space. Due to the
computational burden of having a large number of grid points we then used these
samples to create a smaller grid of points at each age using k-means clustering. The
goal of k-means clustering is to divide L points (i.e., the sample belief states) in M
dimensions (i.e., the partially observable health states) into k clusters so that within-
cluster sum of squares is minimized (Hartigan and Wong (1979)). The centroid of
each cluster then defines a unique grid point. Algorithm 1 gives a description of the
k-means clustering algorithm and an example is given in Figure 5.1.
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Algorithm 1 k-means clustering algorithm for grid development.
Inputs: x sample paths through the belief space; number of grid points at each
age, k
1: for t = 55, . . . 69 do
2: Randomly divide the x sample belief states into k clusters.
3: Calculate the centroid of each cluster and let that be the mean.
4: while convergence is not reached do
5: Cluster each simulated sample belief state with the nearest mean.
6: Calculate the centroid of each cluster and let that be the new mean.
7: end while
8: The k means represent the k grid points for age t.
9: end for
Smallwood and Sondik (1973) presented the first exact method for POMDPs,
known as the “One-Pass Algorithm”. Smallwood and Sondik (1973) shows that the











for some set of vectors αk(t) = [αk1(t), α
k
2(t), . . . , α
k
N(t)], k = 1, 2 . . . , which are re-
ferred to as α-vectors. Each α-vector has an action associated with it; therefore, we
can evaluate each α-vector at a fixed belief state to determine the α-vector that max-
imizes the value function and the optimal action associated with it. However, there
may be many α-vectors in the set that are not needed to define the value function
(i.e. they are not a maximum α-vector over the entire belief space). The algorithm
described in Smallwood and Sondik (1973) defines regions for an α-vector and searches
for a belief where that α-vector is not dominant. The “One-Pass Algorithm” solves
a series of linear programs to try to find a minimal α-vector set. However, we must
solve a linear program for each α-vector in the set, which is computationally expen-
sive since the set of α-vectors grows exponentially in the size of the set of possible
observations.
Cassandra et al. (1994) proposed the “Witness Algorithm”, which also defines
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Figure 5.1: An example of k-means for a simple 2-dimensional case, where the unfilled
points represent the L = 13 sample points and the filled points represent
the k = 3 grid points.
regions for a vector and looks for a point where that vector is not dominant. As
a result, the “Witness Algorithm” only needs to solve one linear program for each
α-vector in the minimal α-vector set, which is an improvement on the “One-Pass
Algorithm”.
In our approach, we draw on the basic idea of the witness algorithm to accelerate
the one-pass algorithm. Terminal rewards define the α-vector in decision epoch T +1.
At each age moving backwards starting from decision epoch T , we use Monahan’s
algorithm (Monahan (1982)) to calculate the set of α-vectors in decision epoch t using
the α-vectors from decision epoch t+ 1. We then eliminate any α-vectors that do not
define the value function at one of the grid points that approximates the belief space,
i.e., each grid point acts as a witness point for one α-vector and thus the number of
α-vectors is limited to the number of grid points. We use our simulation model and
the k-means clustering model to develop a set of grid points that represent the areas
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of the belief space that our patient population is most likely to be, and use those grid
points to calculate a subset of the relevant α-vectors by finding the dominant α-vector
associated with each grid point. After we complete this step, we have developed a
policy, where we determine the (approximated) optimal action at any point in the
belief space by selecting the action associated with the α-vector that maximizes the
value function, αTπ.
5.4 Results
To develop age-dependent grids, we generated 600 randomly sampled patient sam-
ple paths through the belief space for 110 different MiPS policies. The 110 policies
included every combination of the previously recommended schedules described in
Table 5.1 with the following thresholds: {0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40,
0.45, 0.50}. We then used these samples to create a grid of points at each age using
the k-means clustering heuristic in Matlab, where k = 200, L = 66, 000, and M = 5.
As shown in Figure 5.2, we found that at older ages there are more grid points with a
higher belief of having prostate cancer, which agrees with the fact that the prevalence
of prostate cancer increases at older ages.
Patients were screened at each decision epoch from ages 55 to 69. In our exper-
iments, we discretized the continuous observations space of MiPS scores into three
observations: Θ = {[0, .125), [.125, .375), > .375}, which equally divided patients into
low, median, and high risk groups. We evaluated two types of POMDP screening
policies. The first was based on the policy developed using the data-driven sampling
method above to prune α-vectors and create an approximation of the optimal pol-
icy subject to error induced by using a finite set of grid points. The second uses a
risk-based threshold to trigger prostate biopsy based on a patient’s current belief of
having Gleason score > 7 or extraprostatic or lymph node-positive disease (i.e., the
belief the patient is in states OCG3 or EPLN). Under this risk-based POMDP policy
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Table 5.1: Screening schedules for the prostate cancer screening policies used to gen-
erate sample paths. The screening schedule defines the set of decision
epochs during which screening occurs.
Schedule Label Range of Ages (yr) Screening Interval (yr) Source
S1 40-75 5 Ross et al. (2000)
S2 50-75 2 Ross et al. (2000)
S3 50-75 1 Ross et al. (2000),
Andriole et al. (2009)
S4 40,45 - Ross et al. (2000)
50-75 2
S5 40,45 - Ross et al. (2000)
50-75 1
S6 55-69 1 Heijnsdijk et al. (2012)
S7 55-74 1 Heijnsdijk et al. (2012)
S8 55-69 4 Heijnsdijk et al. (2012)
S9 55 - Heijnsdijk et al. (2012)
S10 60 - Heijnsdijk et al. (2012)
S11 65 - Heijnsdijk et al. (2012)
Figure 5.2: The grids generated for ages 55 and 69, where the belief of cancer is
calculated by adding the belief of each of the four cancer states.
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with a risk threshold of x, when πOCG3+πEPLN > x, the patient receives a biopsy. We
found that a risk threshold of 0.35 maximized expected QALYs for the patient. We
evaluated the resulting POMDP policies using our simulation model. We compared
the results to the following six myopic screening policies based on commonly used
thresholds:
• No screening
• PSA with a threshold of 4 ng/mL
• PSA with a threshold of 2 ng/mL to trigger a PCA3 test with a threshold of
25 (patients with a PSA > 10 ng/mL will automatically receive a biopsy)
• PSA with a threshold of 2 ng/mL to trigger a T2:ERG test with a threshold of
10 (patients with a PSA > 10 ng/mL will automatically receive a biopsy)
• High-grade MiPS test with a threshold of 15
• MiPS test with a threshold of 25
A PSA threshold of 4 is common, the two-stage policies were evaluated in Chap-
ter III, and the MiPS and high-grade MiPS thresholds performed well in previous
experiments.
We estimated the terminal reward vector using our simulation model of Chapter III
with 10,000,000 sample paths starting at age 70 from each core state:
αT =
( NC OCG1 OCG2 OCG3 EPLN NRFT PRFT M D
14.062 13.887 13.609 13.532 9.826 14.104 13.592 2.823 0
)
.
Each element of αT is an estimate of expected remaining lifespan for the corresponding
state.
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Figure 5.3 shows the results in terms of QALYs with confidence intervals for
10,000,000 samples. We found that by using the policy generated by our approximated
POMDP solution which accounts for a patient’s entire history of their biomarker
test results, we can gain 181.7 QALYs, which significantly outperformed all myopic
policies. Thus, we found that it is possible to develop screening policies using our
approximated solution technique on a discretized POMDP, and that it results in
health benefits for the patient. The POMDP policy with a risk threshold of 0.35
gained 193.4 QALYs per 1000 men. The difference between these POMDP policies
was not statistically significant. The POMDP approximated solution depends on
the grid selection, while the risk-based POMDP policy does not, suggesting there is
potential of increased gains through better grid selection.
5.5 Conclusions
In this chapter, we presented a new POMDP model to estimate optimal biopsy
screening policies based on a patient’s belief state rather than their latest biomarker
test results. The underlying health states of the patient are not directly observable;
however, their high-grade MiPS results provide some information about their core
health state. Patients were screened annually with the high-grade MiPS test from
ages 55 to 69. Due to the large number of observations and unobservable states, we
presented a data-driven approximation method to solve this POMDP. We found that
it is possible to develop screening policies using our approximated solution technique
on a discretized POMDP, and that it results in significant health benefits for the
patient. We also found that an easier to implement risk threshold based policy has
similar performance to the optimal solution to the discretized POMDP.
Our study has limitations based on assumptions used in the modeling process.
First, active surveillance and radical prostatectomy were assumed to be the only treat-
ment options, because radical prostatectomy is the most common curative treatment,
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Figure 5.3: Expected increase in QALYs per 1000 men compared to no screening
for a range of myopic policies compared to two policies based on our
POMDP with three HG MiPS observations. The first POMDP policy
was generated by our approximated POMDP solution and the second
POMDP policy performs a biopsy when a patient’s belief of having OCG3
or EPLN is ≥ 0.36.
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and patients undergoing radiation therapy have similar health outcomes (Hamdy et al.
(2016)). Lastly, we assumed that each patient receives at most one screening biopsy
in his life. About 7 − 12% of men undergoing biopsy have had a previous negative
biopsy (Nguyen et al. (2010); Thompson et al. (2006)); however, the majority of pa-
tients receive a single biopsy, and cancers detected on second biopsy are typically
less clinically significant. Since our intent is to measure the public health impact of
biomarker screening, we do not believe this assumption significantly influenced our
results.
5.6 Future Work
Both POMDP policies depended on the discretization of the continuous obser-
vation space. In our experiments, we discretized the continuous observation space
into three observations. In the future, we will explore whether expanding the num-
ber of observations in the discrete approximation has an impact on long-term health
outcomes. Additionally, our experiments had approximately 200 grid points for each
age. The POMDP approximated solution depends on the grid selection, while the
risk-based POMDP policy does not. The risk-based POMDP policy outperforming
the approximated POMDP solution which suggests there could be potential addi-
tional health gains that could be achieved through better grid selection. We propose
two different ways to improve the grid. First, we could simply increase the number
of grid points at each age. Second, we could develop a closed-loop algorithm, where
the policy developed by our POMDP approximation technique informs our grid point
selection. A diagram showing how this closed-loop would work is shown in Figure 5.4.
By improving our discretization of the continuous observation space and belief space,
we can observe what impact these parameters have on the policy and the resulting
long-term health outcomes for the patient.
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under a policy to 
get belief vector 























# iterations # grid points
# iterationsstopping criteria
Figure 5.4: Closed-loop diagram showing how we will use the policy generated by our
POMDP approximation technique to develop a new more-relevant grid.
Arrows pointing to a box indicate inputs that are needed in the process.
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CHAPTER VI
A Hidden Markov Model for Optimizing Active
Surveillance Strategies for Low Risk Prostate
Cancer
6.1 Introduction
Although prostate cancers often demonstrate indolent clinical behavior (Miller
et al. (2006)), many men with low-risk tumors still receive surgery or radiation ther-
apy, both of which are associated with potentially serious complications including
incontinence, impotence, and other side effects (Anandadas et al. (2011)). These
complications are particularly distressing given that evidence shows that these men
may not survive longer with surgery or radiation than they do with expectant man-
agement approaches. Active Surveillance is a form of expectant management that
involves monitoring patients by conducting regular clinical exams, biomarker tests,
radiologic imaging, and biopsies. Due to concerns that many men who are diagnosed
with prostate cancer are overtreated, active surveillance has been promoted as a way
for low-risk men to delay and possibly avoid surgery or radiation treatment. However,
many approaches to implementing active surveillance have been recommended and
the best approach is unclear (DallEra et al. (2012)).
Due to a lack of evidence in support of a single optimal active surveillance strat-
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egy, it is left to individual urologists and patients to decide how frequently to conduct
follow-up biopsies. No previous study has made a link between different active surveil-
lance follow-up strategies and the delay in the detection of progression to high-grade
cancer. Risk of progression is one of the most important considerations when weigh-
ing long-term risk for patients on active surveillance. The ideal strategy to minimize
risk of delaying the detection of high-grade cancer progression is to biopsy patients
frequently (e.g. annually as suggested by Tosoian et al. (2011)). However, this risk
competes with the harms of frequent biopsies resulting in pain and anxiety for pa-
tients, and the potential for complications such as infection. Infection rates for biopsy
are approximately 1-2% (Gonzalez et al. (2012)); however, recent studies suggest that
infection rates for patients undergoing active surveillance increases as a function of
the number of biopsies they have received (Ehdaie et al. (2014)). Studies have also
observed discontinuation of active surveillance by patients without signs of progres-
sion (Loeb et al. (2015)) and some have suggested that reducing surveillance biopsies
may encourage compliance with active surveillance (Al Otaibi et al. (2008))
We used a hidden Markov model to evaluate longitudinal data from the Johns
Hopkins Active Surveillance study to estimate initial biopsy sampling error, biopsy
accuracy, and the rate of progression from low to intermediate or high-grade prostate
cancer over time. Note that we use the term “progression” broadly to refer to biologi-
cal progression of cancer grade and the occurrence of de novo cancer. We implemented
a version of the Baum-Welch algorithm tailored to consider uncertainty in the initial
population’s health status due to biopsy sampling error. Next, we used sensitivity
analysis based on simulated data to establish the algorithm converges to accurate pa-
rameter estimates for hidden Markov models. Finally, we used the model to evaluate
all possible follow-up surveillance strategies as well as previously proposed strategies
for active surveillance found in the literature on the basis of mean delay time to
grade progression and the number of planned biopsies over the first 10 years following
85
initiation of active surveillance.
6.2 Model
In this section, we summarize the data from the Johns Hopkins Active Surveil-
lance study; the hidden Markov model we used to estimate initial risk of the active
surveillance cohort, biopsy sampling error, and prostate cancer grade progression; and
how we used these estimates to develop a simulation model to evaluate alternative
active surveillance strategies.
6.2.1 Data
The Johns Hopkins Active Surveillance study collected longitudinal data for men
initially believed to have “favorable risk” prostate cancer. The data includes 1499
men with data collected over 20 years. The enrollment criteria were: clinical stage ≤
T1c, PSA density ≤ 0.15, Gleason score ≤ 6, total positive cores ≤ 2, and single core
positivity ≤ 50%. Due to patient preference, older men with low-risk disease (i.e.,
clinical stage ≤ T2a, PSA < 10 ng/mL, and Gleason score ≤ 6) were also enrolled
in the study. The data collected includes PSA, age, and biopsy results (e.g., Gleason
score, number of positive cores, maximum percentage core involvement). The dataset
used was anonymized with respect to patient identifiers and approval of the University
of Michigan IRB was obtained prior to initiation of the study.
The original dataset included longitudinal data for 1521 patients. We removed
22 patients from the dataset due to missing diagnostic biopsy information. Table 6.1
describes the patient characteristics at diagnosis of the 1499 patients included in the
study. Among men who discontinue active surveillance and receive treatment, 50.9%
received surgery and 46.2% received radiation therapy. The study protocol called
for patients to be biopsied annually. The mean and variance of the time between
biopsies was 14.2 and 60.1 months, respectively. The median number of biopsies per
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patient, including diagnosis biopsy, was 3 and ranged from 1 to 14. Table 6.2 shows
the biopsy characteristics, where we have defined progression to be transition from a
Gleason score ≤ 6 to Gleason score ≥ 7 on biopsy. Due to this definition, we excluded
the six patients diagnosed with Gleason 7 disease from the analysis in Table 6.2.
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Table 6.1: Patient characteristics at time of diagnosis. AS = active surveillance.
Characteristic AS cohort (N = 1499), no. (%)
Age at diagnosis, yr















> 10 85 (5.7)
NA 123(8.2)





> 0.20 114 (7.6)
NA 119 (7.9)
Gleason score at diagnosis
≤ 6 1488 (99.3)
3 + 4 5 (0.3)






















































































































































































































































































































































































































































































































































































































































































































































































































































































6.2.2 Hidden Markov Model for Prostate Cancer Grade Progression
The specific type of model we employ is a hidden Markov model in which patient’s
progress through health states as defined by their prognostic grade groups based on
Gleason score, the most important clinical factor for assessing risk of prostate cancer
mortality. The term hidden refers to the fact that the exact health state of the
patient is unknown in the absence of prostatectomy. The probability of progression
to a higher prognostic grade group is determined by transition probabilities. We
based the model on one-year time periods between state transitions to be consistent
with the highest proposed frequency of biopsies and because that was the planned
frequency of biopsies in the Johns Hopkins study.
In the remainder of this section, we use the notation from Rabiner (1989) to
describe the hidden Markov model. We index annual time periods as t = 0, 1, . . . , T .
The model has states at time period t denoted by st ∈ S ≡ {S0, S1}, where S0
denotes patients with low-grade cancer (defined as Gleason score ≤ 6), and S1 denotes
patients whose cancer has progressed to a higher grade cancer (defined as Gleason
score ≥ 7). Since patients in the high-grade state cannot regress to the low-grade
state the transition probability matrix is that of an absorbing Markov chain:
A =
 P (S0|S0) P (S1|S0)
0 1

These states are not directly observable. At t = 0, patients begin active surveil-
lance under the belief that they are in state S0; however, due to biopsy sampling
error they could be in state S1. We let π = (π0, π1) denote the initial distribution of
patients in states S0 and S1 at their first surveillance biopsy. Biopsies are performed
at each time period (annually). The model has observations o ∈ O ≡ {O0, O1} where
O0 denotes a biopsy observation of Gleason score ≤ 6 and O1 denotes a biopsy obser-
vation of Gleason score ≥ 7 . Biopsies are imperfect due to sampling error and the
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Figure 6.1: Illustration of the state transition and observation process for the hidden
Markov model.
conditional probability of biopsy observations are denoted by the following matrix:
B =
 P (O0|S0) P (O1|S0)
P (O0|S1) P (O1|S1)

If a biopsy result is O1 (Gleason score ≥ 7), the patient exits the system and re-
ceives treatment. Collectively the model parameters for the hidden Markov model
are denoted by λ = (π,A,B). Figure 6.1 illustrates the stochastic active surveillance
process.
We used the Baum-Welch algorithm to compute maximum likelihood estimates for
the hidden Markov model parameters (Rabiner (1989)). The Baum-Welch algorithm
is a special case of the general expectation-maximization (EM) algorithm (Dempster
et al. (1977)), an iterative algorithm that combines forward and backward passes
on a longitudinal observation sequence to find the choice of λ that maximizes the
likelihood of observing the collection of sequences. In our application, we have biopsy
results for a collection of k = 1, . . . , N patients. Each patient, k, results in an




2 . . . O
(k)
Tk
], which represents a patient’s biopsy
results over Tk time periods. We denote the set of N observation sequences as O =
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where we assume that observation sequences between patients are independent.
To describe the Baum-Welch algorithm, we define some additional parameters.
We denote elements of matrices A and B as aij and bij, respectively. First, we define
the forward variable αkt (i) as:




2 , . . . , O
(k)
t , st = Si|λ)




2 , . . . O
(k)
t ,
(until time t) and being in state Si at time t, given the model λ. We use forward
induction to solve for αkt (i):
αk1(i) = πibi(O
(k)













, 2 ≤ t ≤ T − 1, j = 1, 2
Next, we define the backward variable βkt (i) as




t+2, . . . , O
(k)
Tk
|λ, st = Si)
which is the probability of the partial observation sequence from t+1 to Tk, given the
model λ and given the patient is in state Si at time t. We use backward induction to
solve for βkt (i):











βkt+1(j), t = T − 1, T − 2, . . . , 1, i = 1, 2
To define the iterative procedure, Rabiner (1989) defines ξkt (i, j) to be the prob-
ability of patient k being in state Si at time t and state Sj at time t + 1 given the
model λ and observation sequences of patient k, O(k):






γkt (i) is the probability of patient k being in state Si at time t, given the model and







Based on these definitions we can write the following update formulas, which










































The update equation for aij calculates the expected number of transitions from state
Si to state Sj divided by the expected number of transitions from state Si. The
update equation for bj(l) calculates the expected number of times a patient is in state
Sj and observes l divided by the expected number of times a patient is in state Sj.
Finally, the update equation for πi is the expected number of times a patient is in
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state Si at t = 1. The Baum-Welch algorithm uses the above formulas to iteratively
update the parameters of λ. A proof of convergence follows from the convergence
guarantees for the EM algorithm (Rabiner (1989)). However, convergence to a local
optimum is possible since the maximization problem is not strictly convex, and thus
the limiting point for the sequential updates may be sensitive to the starting point.
For this reason we conducted sensitivity analysis using data generated by sampling
from known models to confirm convergence of the Baum-Welch algorithm.
Algorithm 2 Baum-Welch algorithm for parameter estimation.
Input: Initial model parameter estimates λ0 = (A0, B0, π0).
1: Calculate P (O|λ0) using equation 6.1.
2: Calculate λ1 = (A1, B1, π1), which is a function of λ0 using the update equa-
tions 6.2, 6.3, and 6.4.
3: Calculate P (O|λ1) using equation 6.1.
4: v ← 1
5: while P (O|λv)− P (O|λv−1) > 10−6 do
6: v ← v + 1
7: Calculate λv = (Av, Bv, πv), which is a function of λv−1 using equations 6.2,
6.3, and 6.4.
8: Calculate P (O|λv).
9: end while
6.2.3 Model Validation
To further validate the results obtained, we used the base case estimates of our
model to simulate the detection rate based on 10,000 samples assuming annual biopsy
as planned in the Johns Hopkins Active Surveillance study protocol, and compared
the results to the observed detection rates in the Johns Hopkins data.
Next, we conducted experiments based on a hypothetical hidden Markov model
for which we knew the true values for model parameters, and we tested our implemen-
tation of the Baum-Welch algorithm on sampled results for 1375 simulated patient
observation sequences, which is the number of patients in the study who received
their first surveillance biopsy. Since there was missing data in the Johns Hopkins Ac-
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tive Surveillance study resulting from patients who discontinued active surveillance in
the absence of grade progression, we sought to test the assumption that the missing
data was not informative. Therefore, we censored the data for simulated observa-
tion sequences according to the observed mean rate of patients discontinuing active
surveillance without grade progression. We then ran the Baum-Welch algorithm on
the simulated data and compared the parameter estimates to the true parameters
used to generate the simulated data.
6.2.4 Sensitivity Analysis
To validate that the resulting parameter estimates were not sensitive to the initial
starting points, we varied our initial estimate for each parameter using a range of
±0.1 with an upper limit of 0.99. We then ran the Baum-Welch algorithm on each
new set of initial estimates, and compared the resulting parameter estimates.
Additionally, we performed bootstrapping analysis for which we randomly sampled
1375 patients with replacement from the Johns Hopkins dataset. We generated 30
different bootstrap samples and ran the Baum-Welch algorithm on each sample, and
compared the resulting parameter estimates.
6.2.5 Simulation Model
The hidden Markov model can be used to compute statistical estimates of health
outcomes such as the mean delay in detection of grade progression for patients who
experienced grade progression. The delay time depends on the hidden Markov model
parameter estimates, λ, which includes the initial probability a patient has Gleason
Score ≤ 6 (i.e., π0) or Gleason Score ≥ 7 (i.e., π1) at the time of diagnosis, the
transition probability from Gleason Score ≤ 6 to Gleason Score ≥ 7 (i.e., a01), and
the sensitivity (i.e., b11) and specificity of biopsy (i.e., b00). Together with the active
surveillance biopsy schedule these parameters collectively govern the time to reach the
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high-grade cancer state and subsequent detection of grade progression. We defined
the biopsy schedule as a vector, ~x = (x1, x2, . . . , xT ) of binary decision variables where
xt = 1 indicates a biopsy is planned at period t and xt = 0 indicates that a biopsy is
not planned at period t. The problem of determining the optimal active surveillance









where D(ω, ~x) denotes the delay time for detection of progression for a given random
sample path, ω, that indexes all the outcomes of the hidden Markov model including
the true state at each time period, st, sampled using transition probability matrix A
and the biopsy outcome, sampled using the observation matrix, B. The expectation
is with respect to the hidden Markov model and can be estimated by random sam-
pling. The parameter δ is a limit on the number of biopsies allowed over the T year
time horizon. By varying δ, the set of Pareto optimal schedules can be obtained. The
number of possible active surveillance strategies is 2T and the optimization problem
can be solved via total enumeration. We simulated all possible strategies and iden-
tified those strategies that were non-dominated, i.e., those strategies for which no
other strategy simultaneously recommended fewer biopsies and had lower mean time
to detect high-grade cancer.
6.3 Results
6.3.1 Hidden Markov Model Analysis
To initiate the Baum-Welch algorithm, we needed initial estimates of the model
parameters λ = (π,A,B). These estimates are not directly observable in the dataset,
because biopsies are imperfect; thus, we used estimates from the literature. Alam et al.
(2015) studied reclassification rates for men in the Johns Hopkins Active Surveillance
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study, and found that the majority of men are reclassified within the first two years,
most likely due to initial biopsy misclassification. We estimated annual progression
rate from Gleason score ≤ 6 to Gleason score ≥ 7 to be 5% by calculating the
rate of progression at patients’ third through thirteenth biopsies. Estimates for the
sensitivity and specificity of biopsy to Gleason score ≥ 7 disease were calculated to be
62.5% and 89.4%, respectively, based on data reported in Epstein et al. (2012), which
compared biopsy results to Gleason score at radical prostatectomy. Finally, using
data reported in Epstein et al. (2012), we estimated that 74.9% of patients diagnosed
with Gleason score ≤ 6 disease on biopsy have Gleason score ≤ 6 disease at radical
prostatectomy, while 25.1% have Gleason score ≥ 7 disease at radical prostatectomy.
Based on these estimates from the literature, we used the following parameter starting




 , B =
 0.894 0.106
0.375 0.625
 , π = [ 0.749 0.252 ]
After estimating these initial parameter estimates, we ran the Baum-Welch algo-
rithm with a stopping criteria defined by a tolerance of 10−6 on the difference between
the log likelihoods for consecutive iterations. The resulting parameter estimates from




 , B̃ =
 0.986 0.014
0.390 0.610
 , π̃ = [ 0.866 0.134 ]
Thus, we found that annual progression rate from Gleason score ≤ 6 to Gleason
score ≥ 7 to be 4%; the sensitivity and specificity of biopsy to Gleason score ≥ 7
disease to be 61.0% and 98.6%, respectively; and the initial proportion of patients
undergoing active surveillance with Gleason score≤ 6 disease at their first surveillance
biopsy to be 86.6%.
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Table 6.3: Results comparing hidden Markov model parameter estimates from the
Baum-Welch algorithm to the true model parameter estimates from a
known model.






To validate the results obtained, we used the base case estimates of our model to
simulate the detection rate of Gleason score ≥ 7 disease assuming annual biopsy as
planned in the Johns Hopkins Active Surveillance study protocol. Figure 6.2 compares
the model-based results and the observed results. Model predicted results were based
on 10,000 samples. The confidence intervals for the observed results are reported in
the figure. There was no statistically significant difference between the predicted and
observed biopsy detection rate at the p=0.05 threshold.
Results for the hypothetical hidden Markov model for which the true values for
model parameters are known are presented in Table 6.3, which shows the true model
parameters from the known model and the 95% confidence interval for our model
parameter estimates based on the Baum-Welch algorithm applied to the simulated
sequences. The true value of π0, b11, and b00 all lie within the 95% confidence intervals,
while the true value of a01 is 0.040 and does not lie within the 95% confidence interval,
0.033− 0.039.
6.3.3 Sensitivity Analysis
To validate that the resulting estimates are not sensitive to the starting points, for
each parameter, we varied the initial estimates of the model parameters in the range
of ±0.1 with an upper limit of 0.99. We found the resulting parameter estimates
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Figure 6.2: Comparison of Gleason score ≥ 7 detection rates predicted by the sim-
ulation model to the observed rate in the Johns Hopkins study. Model
predicted results were based on 10,000 samples. The confidence intervals
for the observed results are shown, and the confidence intervals for the
model predicted results are too small to see on the figure.
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Table 6.4: Bootstrapping results.
Parameter Mean 95% Confidence Interval
a00 0.964 [0.960, 0.968]
b00 0.984 [0.980, 0.988]
b11 0.611 [0.587, 0.635]
π0 0.867 [0.857, 0.876]
varied by less than 0.5% from the values calculated using our original starting points,
suggesting that starting points did not significantly impact our parameter estimates.
For our bootstrapping analysis we generated 30 different bootstrap samples and
ran the Baum-Welch algorithm on each sample. The resulting 95% confidence in-
tervals based on bootstrapping are presented in Table 6.4, with b11 having the most
variation.
6.3.4 Optimization of Active Surveillance Strategies
The Baum-Welch algorithm calculated that 86.6% of patients were correctly di-
agnosed to have Gleason score ≤ 6 and 13.4% of patients were undersampled at their
first surveillance biopsy and actually had Gleason score ≥ 7. In our simulation model
we assumed diagnosis occurred 12 months prior to the first surveillance biopsy. Thus,
based on hidden Markov model parameters from the Baum-Welch algorithm we es-
timated that 90.22% of patients had Gleason score ≤ 6 at diagnosis, and 9.78% of
patients were undersampled and had Gleason score ≥ 7 at diagnosis.
We used the hidden Markov model parameter estimates to simulate mean delay
time in detecting progression among patients who progress to high-grade cancer over a
10-year period following diagnosis of prostate cancer for all 210 possible active surveil-
lance strategies. Our simulation model found that 40% of patients would progress
to high-grade cancer in 10 years, and that a strategy that performs annual biopsies
(the Johns Hopkins strategy) takes a mean of 14.1 months to detect progression. The
strategy that minimized the mean delay time for each choice of planned number of
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Figure 6.3: Simulation results for optimal active surveillance strategies and published
strategies based on the estimated hidden Markov model parameters. In-
cremental time to detection and the reduction in biopsies are relative
to an annual biopsy strategy. (Note: mean time to detection of grade
progression for annual biopsy plan = 14.1 months)
biopsies over 10 years are plotted in Figure 6.3, which shows the incremental time to
detection and the reduction in biopsies relative to a strategy that performs annual
biopsies. We have also included active surveillance strategies from the literature.
University of California, San Francisco (UCSF) recommends a biopsy 1 year after
diagnosis, then every 1 to 2 years. We modeled two versions of this policy: UCSF1
performs a biopsy after 1 year, then every 1.5 years and UCSF2 performs a biopsy af-
ter 1 year, then every 2 years. PRIAS/University of Toronto (UT) performs a biopsy
after 1, 4, 7, and 10 years (van den Bergh et al. (2007)). Figure 6.3 displays that
UCSF performs well compared to the optimal policies, while the PRIAS/UT policy
increases mean time to detection by 5.2 months compared to our optimal policy that
performs biopsies after 1, 3, 5, and 8 years.
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6.4 Conclusions
Many experts have called for the use of active surveillance to address overtreat-
ment concerns for men with low-risk prostate cancer. active surveillance delays and
possibly avoids immediate treatment via surgery or radiation therapy until and unless
there is evidence that the disease has progressed; however, it comes with a burden to
patients due to the need to conduct follow-up clinical exams, tests, and surveillance
biopsies. Biopsies in particular are a significant burden to patients. The intensiveness
of follow-up determines the frequency of clinical exams, tests, and biopsies. In the ab-
sence of randomized trials comparing active surveillance pathways there is no consen-
sus among urologists about the best way to trade-off the burden of surveillance with
the benefits of avoiding cancer progression (Lawrentschuk and Klotz (2011)). Fur-
thermore, little is known about the factors that determine why men initially choose
active surveillance over immediate treatment (surgery or radiation therapy), or why
they choose to abandon active surveillance. We provide a new active surveillance
precision medicine (ASPM) model for quantifying the trade-off between benefits and
harms of various active surveillance strategies. These decisions must trade-off between
the potential long-term benefits of detecting disease progression with the burden of
surveillance, including patient anxiety, and the potential harms and side effects of
biopsies (e.g. pain, anxiety, and hospitalization for infection in 2–3% of cases).
Our results suggest that there are diminishing benefits as the number of biopsies
increases. It is interesting to note that we can eliminate six biopsies in 10 years, which
has a substantial impact on the patient, while only increasing the time to detection
by 11.4 months. Additionally, the optimal biopsy schedules tend to perform more
biopsies in the beginning to catch patients misdiagnosed with low-risk cancer due to
undersampling of biopsies.
There are multiple definitions of progression for prostate cancer, including defini-
tions based on increase in PSA, PSA velocity and density, and tumor volume. Grade
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progression, which refers to a change in Gleason score, is a definitive form of progres-
sion recognized by all published active surveillance guidelines. However, currently
there is debate about whether grade progression is possible, or if the occurrence of
higher grade cancer on biopsy occurs due to biopsy sampling error. Some studies
suggest that that a combination of sampling error and progression are responsible
for increased grade detection over time (Epstein et al. (2012); Inoue et al. (2014)).
Our findings lend additional evidence to these studies, suggesting a combination of
sampling error and progression are responsible for detection of higher grade cancers
in the future.
A chief concern about active surveillance is the possibility that prostate cancer
progresses in the interval of time between biopsies or that progression is missed due
to imperfect sensitivity of biopsies. The potential for undetected progression raises
questions about health outcomes for patients on active surveillance who progress and
receive treatment. Studies comparing radical prostatectomy outcomes for patients
initially on active surveillance to patients receiving radical prostatectomy immediately
following diagnosis have shown that low-risk men who receive annual biopsy on active
surveillance do not have worse surgery outcomes (Tosoian et al. (2011)). Additionally,
Klotz et al. (2014) reported that patients undergoing active surveillance with biopsies
every 3 to 4 years had mortality rates consistent with patients who received initial
definitive treatment. Assuming a uniform distribution of progression times during
the 3 to 4 years intervals would suggest delays of 1.5 to 2 years in detecting grade
progression may not have a clinically significant impact.
The most related work to ours is an article by Inoue et al. (2014) in which the au-
thors develop a statistical model based on the assumption that patients may progress
prior, during, or following the active surveillance study period. The authors’ ap-
proach assumes that the risk of progression is stationary and the change point (at
which progression occurs) can be modeled as a multinomial distribution. Their model
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is premised on the assumption that the misclassification error is known, or can be
estimated, and the authors’ results show that these estimates are critically important.
Unfortunately such estimates are never available in practice and must be estimated
from other study populations. Our proposed approach relaxes this assumption, pro-
viding estimates of misclassification error that can be used to inform the optimal
strategy for active surveillance.
One limitation is that our results apply to patients with “favorable risk” prostate
cancer (i.e., clinical stage≤ T1c, PSA density≤ 0.15, Gleason score≤ 6, total positive
cores ≤ 2, and single core positivity ≤ 50%) and older men with low-risk disease (i.e.,
clinical stage ≤ T2a, PSA < 10, and Gleason score ≤ 6), since these are the patients
that were enrolled in the Johns Hopkins Active Surveillance study and thus there
is a need to validate our findings on other active surveillance studies; however, this
initial study lays the groundwork for such future validation work. A related limitation
is that our study is based on a single active surveillance study. Missing data from
patients that drop out of the study without progression could confound the results,
although our sensitivity analysis helped to mitigate this concern. Finally, our results
provide the trade-off between number of biopsies and mean delay time to detection
of progression; however, the amount of time that is considered safe to delay detection
is not known. Nevertheless, data from the literature suggests that short delay times
may not have significant clinical impact. Metastases is a better endpoint, but the data
needed to fit a hidden Markov model with this endpoint does not yet exist. These
limitations notwithstanding, we believe this study provides important evidence about
the trade-off between varying active surveillance strategies and the optimal timing of
biopsies during active surveillance. In the future, we would like to use datasets from
other active surveillance studies to study optimal biopsy strategies for intermediate-
risk patients.
While annual biopsy for low-risk men on active surveillance is associated with the
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shortest time to detection of Gleason ≥ 7 disease, several alternative strategies may
allow for less frequent biopsy without sizable increases in time to detecting grade
progression. It is interesting to note that by performing biopsies in 1, 3, 5, and 8
years after diagnosis, we can eliminate six biopsies in 10 years, which has a substantial
impact on the patient’s quality of life and risk of infection, while only increasing the
time to detection by 11.4 months. Additionally, the optimal biopsy schedules tend to
perform more biopsies in the beginning to catch patients misdiagnosed with low-risk
cancer. Moreover, we found that while the UCSF policy performed almost as well as
optimal policies with the same number of biopsies over a 10 year period, we could
reduce the time to detection by an additional 5.2 months compared to the PRIAS/UT




Prostate cancer screening can improve patient outcomes by catching cancer at an
early stage when health outcomes are most favorable for patients; however, widespread
prostate cancer screening has led to unnecessary biopsies caused by false-positive
PSA results and the overtreatment of low-risk prostate cancer with harsh curative
treatments. In this dissertation we presented a series of prostate cancer models to
evaluate the use of new technologies for prostate cancer screening to better select men
for prostate biopsy, as well as the optimal timing of surveillance biopsies for men with
low-risk disease undergoing active surveillance. Following is a summary of the most
important findings from Chapters III, IV, V, and VI.
In Chapter III, we developed and validated a new partially observable Markov
model that considers prostate cancer screening and treatment decisions for a cohort
of men, starting at age 40, through to end of life. We used this model to exam-
ine alternative choices of two-stage biomarker-based screening strategies based on
newly discovered biomarkers with varying thresholds. The screening strategy with a
PSA threshold of 2 ng/mL and a second biomarker with high-grade sensitivity and
specificity of 0.86 and 0.62, respectively, increased the number of QALYs per 1000
men by 19 QALYs compared to no screening and by 7 QALYs compared to using
the PSA test alone with a threshold of 4 ng/mL. Our model predicts one prostate
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cancer death averted per 200 men screened. In our one-way sensitivity analysis, we
found that other-cause mortality had the greatest impact on the expected increase
in QALYs relative to no screening, suggesting that the presence of comorbidity is
an important consideration when determining the optimal prostate cancer screening
strategy.
In our analysis, we found that many different screening strategies performed simi-
larly in terms of QALYs; however, it is possible to distinguish these similar screening
strategies by looking at additional performance measures that may better account
for patient preferences. For example, some strategies that achieved similar QALYs
varied significantly in rates of biopsy and prostate cancer deaths, with reductions in
prostate cancer deaths coming at the expense of a greater biopsy rate. This trade-
off emphasizes the importance of a shared decision making approach to account for
patient preferences regarding risk of prostate cancer mortality and harms from biopsy.
Identifying biomarkers and risk thresholds optimized for identification of high-
grade cancers had the greatest impact on measures of performance in the screening
setting. Combining new biomarkers with PSA has the potential to reduce the number
of screening biopsies (thus decreasing overdiagnosis) and decrease the rate of prostate
cancer mortality. The sensitivity analysis suggests our conclusions are robust with
respect to plausible variation in model parameters.
In Chapter IV, we developed a Markov model to evaluate the cost-effectiveness
of using MRI in a screening setting. We estimated the number of prostate cancer
deaths averted, QALYs, and total cost for each strategy. Additionally, we estimated
the ICERs. Interestingly, the strategies that performed a standard biopsy on negative
MRI were more expensive and less effective than strategies that perform no biopsy
on negative MRI. Based on our study, MRI as an intermediate test in the screening
of men for prostate cancer is cost-effective assuming a willingness-to-pay threshold
of $100,000/QALY threshold. The most efficient strategy was the use of MRI if
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PSA > 4 ng/mL, followed by combined biopsy if MRI was positive and no biopsy if
MRI was negative, using a PI-RADS threshold of 3 to indicate a positive MRI (ICER:
$23,483/QALY gained). These results were robust over a range of sensitivity analyses
and were maintained even if the sensitivity and specificity of MRI and combined
biopsy were reduced by 19 percentage points. This helps to establish the viability
of MRI in a non-academic medical center setting where radiologists may be less
experienced with MRI. Overall, our findings suggest that MRI appears to be a viable
approach for early detection of prostate cancer from a cost-effectiveness perspective.
In Chapter V, we developed a new POMDP model to investigate optimal prostate
cancer screening decisions using new biomarkers based on a patient’s belief state
rather than making decisions based solely on a patient’s most recent test results. The
belief state is calculated using Bayesian updating and comprises a patient’s complete
history of biomarker test results. We solved an approximation of the POMDP, which
maximized total expected QALYs, based on a data-driven sampling approach to cre-
ate a set of grid points in the belief space, and evaluated the resulting policy using
our simulation model. Although exact solutions to the POMDP were not possible, we
showed the grid based approximation could be solved to optimality. We also found
that it is possible to develop approximate POMDP solutions based on data about fre-
quently visited parts of the belief space, and that basing screening decisions on belief
estimates that use the complete history of biomarker results may improve screening.
In Chapter VI, we used a hidden Markov model to estimate initial biopsy sam-
pling error, biopsy accuracy, and the rate of progression from low to intermediate
or high-grade prostate cancer over time based on longitudinal data from the Johns
Hopkins Active Surveillance study. We used maximum likelihood estimation based
on the Baum-Welch algorithm to estimate the hidden Markov model parameters and
sensitivity analysis to establish robustness of the results. We used the resulting model
to evaluate all possible follow-up surveillance strategies as well as previously proposed
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strategies for active surveillance found in the literature on the basis of mean delay
time to grade progression and the number of planned biopsies over the first 10 years
following initiation of active surveillance.
While annual biopsy for low-risk men on active surveillance is associated with the
shortest time to detection of Gleason ≥ 7 disease, several alternative strategies may
allow for less frequent biopsy without sizable increases in time to detecting grade
progression. In particular, performing biopsies in 1, 3, 5, and 8 years after diagnosis
reduces the number of planned biopsies in 10 years by 6 compared to an annual biopsy
schedule, while only increasing the mean time to detection by 11.4 months. We found
that while the UCSF policy performed almost as well as our optimal policies, we could
reduce the time to detection by an additional 5.2 months compared to the PRIAS/UT
policy while performing the same number of biopsies in 10 years.
Chapters III, IV, and V of this dissertation have limitations based on assump-
tions used in the modeling process. First, estimates of sensitivity and specificity for
biomarkers can be dataset-dependent, as the estimates come from different datasets
and, therefore, may have different biases; however, our analysis still provides useful
insights into how the sensitivity and specificity of biomarkers impact long-term health
outcomes. Second, there is the potential for bias in the data we used to estimate MRI
results because the population used includes patients with previous negative biopsies
in addition to biopsy-näıve patients; however, by using the estimates based on the
larger patient population we were able to obtain better estimates of sensitivity and
specificity. Our sensitivity analysis further confirms our conclusions are not sensitive
to this assumption.
Another potential limitation is that we assumed each patient receives at most one
screening biopsy in his life. About 7 − 12% of men undergoing biopsy have had a
previous negative biopsy (Nguyen et al. (2010); Thompson et al. (2006)); however, the
majority of patients receive a single biopsy, and cancers detected on second biopsy are
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typically less clinically significant. Since our intent is to measure the public health
impact of prostate cancer screening, we do not believe this assumption significantly
influenced our results. Another possible limitation is the inconsistent definition of
clinically significant prostate cancer in the literature. For example, Siddiqui et al.
(2015) defined clinically significant disease as high-volume Gleason 3+4 or Gleason
≥ 4 + 3, while Grey et al. (2015) defined clinically significant disease to be cancer
core involvement ≥ 6 mm or the presence of any Gleason pattern 4. In our model,
we considered clinically significant disease to be Gleason score ≥ 7. Finally, the only
curative treatment included in our model was radical prostatectomy, because it is the
most common curative treatment, and patients undergoing radiation therapy have
similar health outcomes (Hamdy et al. (2016)).
One potential limitation of Chapter VI is that our results apply to patients with
“favorable risk” prostate cancer (i.e., clinical stage ≤ T1c, PSA density ≤ 0.15,
Gleason score ≤ 6, total positive cores ≤ 2, and single core positivity ≤ 50%) and
older men with low-risk disease (i.e., clinical stage ≤ T2a, PSA < 10, and Gleason
score ≤ 6), since these are the patients that were enrolled in the Johns Hopkins
Active Surveillance study and thus there is a need to validate our findings on other
active surveillance studies; however, this initial study lays the groundwork for such
future validation work using other populations with different risk profiles. A related
limitation is that our study is based on a single active surveillance study. Missing
data from patients that drop out of the study without progression could confound
the results, although our sensitivity analysis helps to mitigate this concern. Finally,
our results provide the trade-off between number of biopsies and mean delay time to
detection of progression; however, the amount of time that is considered safe to delay
detection is not known. Nevertheless, data from the literature suggests that short
delay times may not have significant clinical impact.
There are several possible research extensions from this dissertation. In our work
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we have shown that new biomarkers provide clinical benefits to patients when used
in conjunction with the PSA test; however, in the future it would be valuable to
evaluate the cost-effectiveness of these new biomarkers for prostate cancer screening.
Additionally, we evaluated the cost-effectiveness of MRI for prostate cancer screening
for men from ages 55 to 69 with two year screening intervals; however, it would be
interesting to further investigate the impact of screening ages on the cost-effectiveness
of MRI. Furthermore, we studied the optimal use of new biomarkers and MRI in
patients with elevated PSA with a fixed PSA threshold. Since PSA naturally increases
as a patient ages, it would be beneficial to evaluate age-dependent PSA thresholds
to trigger these secondary tests. Finally, it would be beneficial to validate our active
surveillance precision medicine (ASPM) model on other cohorts of patients including
intermediate risk patients, which would allow our results to be informative for a larger
portion of the patient population.
In conclusion, we have provided important insights into how new technologies,
like molecular biomarkers and MRI, can be used to supplement the PSA test for the
early detection of prostate cancer, as well as the optimal timing of prostate biop-
sies for men with low-risk prostate cancer undergoing active surveillance. By using
new technologies to better select men for biopsy and by improving active surveillance
strategies, physicians can reduce the harms of prostate cancer screening (e.g., un-
necessary biopsies and overtreatment of low-risk disease) while continuing to reduce
prostate cancer deaths through screening and early detection. Finally, the work pre-
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